Envista (NVST) 10-Q 3 Aug 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jul. 01, 2022	Jul. 29, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jul. 01, 2022
Document Transition Report	false
Entity File Number	001-39054
Entity Registrant Name	ENVISTA HOLDINGS CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	83-2206728
Entity Address, Address Line One	200 S. Kraemer Blvd., Building E
Entity Address, City or Town	Brea,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92821-6208
City Area Code	714
Local Phone Number	817-7000
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	NVST
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		163,390,533
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001757073

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 523.1	$ 1,073.6
Trade accounts receivable, less allowance for credit losses of $19.6 and $20.7, respectively	372.8	331.9
Inventories, net	286	263.8
Prepaid expenses and other current assets	202.3	154.3
Assets held for sale	4.1	12.2
Total current assets	1,388.3	1,835.8
Property, plant and equipment, net	264.1	264.1
Operating lease right-of-use assets	130.5	128.1
Other long-term assets	212.4	167.8
Goodwill	3,389.7	3,132
Other intangible assets, net	1,076	1,046.4
Total assets	6,461	6,574.2
Current liabilities:
Short-term debt	508.6	432.4
Trade accounts payable	182.7	185.8
Accrued expenses and other liabilities	539.4	562.3
Operating lease liabilities	23.8	23.7
Liabilities held for sale	1.7	4
Total current liabilities	1,256.2	1,208.2
Operating lease liabilities	123.4	120.4
Other long-term liabilities	201.3	304.2
Long-term debt	864.1	883.4
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value, 15.0 million shares authorized; no shares issued or outstanding at July 1, 2022 and December 31, 2021	0	0
Common stock - $0.01 par value, 500.0 million shares authorized; 163.3 million shares issued and 162.8 million shares outstanding at July 1, 2022; 162.0 million shares issued and 161.6 million outstanding at December 31, 2021	1.6	1.6
Additional paid-in capital	3,678.4	3,732.6
Retained earnings	610.3	466.9
Accumulated other comprehensive loss	(274.3)	(143.5)
Total Envista stockholders’ equity	4,016	4,057.6
Noncontrolling interests	0	0.4
Total stockholders’ equity	4,016	4,058
Total liabilities and stockholders’ equity	$ 6,461	$ 6,574.2

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for credit losses	$ 19.6	$ 20.7
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred shares authorized (in shares)	15,000,000	15,000,000
Preferred shares issued (in shares)	0	0
Preferred shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	163,300,000	162,000,000
Common stock, shares outstanding (in shares)	162,800,000	161,600,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended			6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021		Jul. 01, 2022	Jul. 02, 2021
Income Statement [Abstract]
Sales	$ 645.8	$ 637.2		$ 1,277.2	$ 1,249.8
Cost of sales	276	268.6		533.3	522.8
Gross profit	369.8	368.6		743.9	727
Operating expenses:
Selling, general and administrative	279.5	259.4		537.7	496.9
Research and development	25.1	25.9		49.5	51.7
Operating profit	65.2	83.3		156.7	178.4
Nonoperating income (expense):
Other income	0.3	0.3		0.6	0.6
Interest expense, net	(6.4)	(13.6)		(12.3)	(31.6)
Income before income taxes	59.1	70		145	147.4
Income tax expense (benefit)	14.6	(9)		30.1	6.6
Income from continuing operations, net of tax	44.5	79		114.9	140.8
Income from discontinued operations, net of tax (refer to Note 3)	2.6	11.1		7.1	21
Net income	$ 47.1	$ 90.1		$ 122	$ 161.8
Earnings per share:
Earnings from continuing operations - basic (in USD per share)	$ 0.27	$ 0.49		$ 0.71	$ 0.88
Earnings from continuing operations - diluted (in USD per share)	0.25	0.44		0.64	0.79
Earnings from discontinued operations - basic (in USD per share)	0.02	0.07		0.04	0.13
Earnings from discontinued operations - diluted (in USD per share)	0.01	0.06		0.04	0.12
Earnings - basic (in USD per share)	0.29	0.56		0.75	1.01
Earnings - diluted (in USD per share)	$ 0.26	$ 0.51	[1]	$ 0.68	$ 0.91
Average common stock and common equivalent shares outstanding:
Basic (in shares)	162.9	161.2		162.6	160.8
Diluted (in shares)	178.5	178.4		179.2	177.2
[1]* Earnings per share is computed independently for earnings per share from continuing operations and earnings per share from discontinued operations. The sum of earnings per share from continuing operations and earnings per share from discontinued operations does not equal earnings per share due to rounding.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 47.1	$ 90.1	$ 122	$ 161.8
Other comprehensive (loss) income, net of income taxes:
Foreign currency translation adjustments	(72.9)	14.4	(132.5)	(39.3)
Cash flow hedge adjustments	0.5	1.1	1.9	2.5
Pension plan adjustments	(0.1)	(0.5)	(0.2)	(0.3)
Total other comprehensive (loss) income, net of income taxes	(72.5)	15	(130.8)	(37.1)
Comprehensive (loss) income	$ (25.4)	$ 105.1	$ (8.8)	$ 124.7

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Millions	Total	Total Envista Equity	Total Envista Equity Adjustment	Total Envista Equity Adjusted balance	Common Stock	Common Stock Adjusted balance	Additional Paid-in Capital	Additional Paid-in Capital Adjustment	Additional Paid-in Capital Adjusted balance	Retained Earnings	Retained Earnings Adjustment	Retained Earnings Adjusted balance	Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Adjusted balance	Noncontrolling Interests	Noncontrolling Interests Adjusted balance
Balance, beginning of period at Dec. 31, 2020		$ 3,720.6			$ 1.6		$ 3,684.4			$ 126.4			$ (91.8)		$ 0.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award activity		6.7					6.7
Net income		71.7								71.7
Other comprehensive income (loss)		(52.1)											(52.1)
Balance, end of period at Apr. 02, 2021		3,746.9			1.6		3,691.1			198.1			(143.9)		0.4
Balance, beginning of period at Dec. 31, 2020		3,720.6			1.6		3,684.4			126.4			(91.8)		0.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 161.8
Other comprehensive income (loss)	$ (37.1)												(37.1)
Balance, end of period at Jul. 02, 2021		3,868.5			1.6		3,707.6			288.2			(128.9)		0.4
Balance, beginning of period at Dec. 31, 2020		3,720.6			1.6		3,684.4			126.4			(91.8)		0.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	Accounting Standards Update 2020-06 [Member]
Balance, end of period at Dec. 31, 2021	$ 4,058	4,057.6	$ (56.4)	$ 4,001.2	1.6	$ 1.6	3,732.6	$ (77.8)	$ 3,654.8	466.9	$ 21.4	$ 488.3	(143.5)	$ (143.5)	0.4	$ 0.4
Balance, beginning of period at Apr. 02, 2021		3,746.9			1.6		3,691.1			198.1			(143.9)		0.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award activity		16.5					16.5
Net income	90.1	90.1								90.1
Other comprehensive income (loss)	15	15											15
Balance, end of period at Jul. 02, 2021		3,868.5			1.6		3,707.6			288.2			(128.9)		0.4
Balance, beginning of period at Dec. 31, 2021	4,058	4,057.6	(56.4)	4,001.2	1.6	1.6	3,732.6	(77.8)	3,654.8	466.9	21.4	488.3	(143.5)	(143.5)	0.4	0.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Change in noncontrolling interest															(0.4)
Common stock-based award activity		13.1					13.1
Net income		74.9								74.9
Other comprehensive income (loss)		(58.3)											(58.3)
Balance, end of period at Apr. 01, 2022		4,030.9			1.6		3,667.9			563.2			(201.8)			0
Balance, beginning of period at Dec. 31, 2021	4,058	4,057.6	$ (56.4)	$ 4,001.2	1.6	$ 1.6	3,732.6	$ (77.8)	$ 3,654.8	466.9	$ 21.4	$ 488.3	(143.5)	$ (143.5)	$ 0.4	0.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	122
Other comprehensive income (loss)	(130.8)												(130.8)
Balance, end of period at Jul. 01, 2022	4,016	4,016			1.6		3,678.4			610.3			(274.3)
Balance, beginning of period at Apr. 01, 2022		4,030.9			1.6		3,667.9			563.2			(201.8)			$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award activity		10.5					10.5
Net income	47.1	47.1								47.1
Other comprehensive income (loss)	(72.5)	(72.5)											(72.5)
Balance, end of period at Jul. 01, 2022	$ 4,016	$ 4,016			$ 1.6		$ 3,678.4			$ 610.3			$ (274.3)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021
Cash flows from operating activities:
Net income	$ 122	$ 161.8
Noncash items:
Depreciation	16.1	19.9
Amortization	50.3	42
Allowance for credit losses	3.6	3.6
Stock-based compensation expense	15.8	14.3
Gain on sale of property, plant and equipment	(1.1)	0
Gain on sale of KaVo treatment unit and instrument business	(8.9)	0
Restructuring charges	3.8	0.3
Impairment charges	4.9	4.1
Amortization of right-of-use assets	11.2	14.3
Amortization of debt discount and issuance costs	2	12
Change in trade accounts receivable	(56.6)	(1.5)
Change in inventories	(29.5)	(47.9)
Change in trade accounts payable	5.9	(23.5)
Change in prepaid expenses and other assets	(17.4)	(7.2)
Change in accrued expenses and other liabilities	(80.9)	(34.2)
Change in operating lease liabilities	(15.5)	(20.7)
Net cash provided by operating activities	25.7	137.3
Cash flows from investing activities:
Acquisition, net of cash acquired	(569.8)	0
Payments for additions to property, plant and equipment	(31.9)	(28.5)
Proceeds from sale of KaVo treatment unit and instrument business, net	28.8	0
All other investing activities, net	(13.6)	5.7
Net cash used in investing activities	(586.5)	(22.8)
Cash flows from financing activities:
Payment of debt issuance and other deferred financing costs	0	(2.3)
Proceeds from borrowings	0.3	0
Repayment of borrowings	(0.5)	(475.6)
Proceeds from stock option exercises	15.4	13.8
Tax withholding payment related to net settlement of equity awards	(8.1)	(5.3)
All other financing activities	0	6.3
Net cash provided by (used in) financing activities	7.1	(463.1)
Effect of exchange rate changes on cash and cash equivalents	3.2	13.6
Net change in cash and cash equivalents	(550.5)	(335)
Beginning balance of cash and cash equivalents	1,073.6	888.9
Ending balance of cash and cash equivalents	523.1	553.9
Supplemental data:
Cash paid for interest	13.8	22.1
Cash paid for taxes	52.6	51.1
ROU assets obtained in exchange for operating lease obligations	$ 18.3	$ 10.8

Business And Basis Of Presentat

Business And Basis Of Presentation	6 Months Ended
	Jul. 01, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	BUSINESS AND BASIS OF PRESENTATION Business Overview The Company provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, as well as to improve the aesthetics of the human smile. The Company is a worldwide provider of a broad range of dental implants, orthodontic appliances, general dental consumables, equipment and services and is dedicated to driving technological innovations that help dental professionals improve clinical outcomes and enhance productivity. The Company operates in two business segments: Specialty Products & Technologies and Equipment & Consumables. The Company’s Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Company’s Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products. Basis of Presentation All revenues and costs as well as assets and liabilities directly associated with the business activity of the Company are included in the financial statements. All significant intercompany accounts and transactions between the businesses comprising the Company have been eliminated in the accompanying Condensed Consolidated Financial Statements. The Condensed Consolidated Financial Statements included herein have been prepared by the Company without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The accompanying Condensed Consolidated Financial Statements contain all adjustments (consisting of only normal recurring adjustments and reclassifications to conform to current year presentation) necessary to present fairly the financial position of the Company as of July 1, 2022 and December 31, 2021, and its results of operations for the three and six month periods ended July 1, 2022 and July 2, 2021 and cash flows for the six month periods ended July 1, 2022 and July 2, 2021. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Consolidated and Combined Financial Statements and accompanying notes for the three years ended December 31, 2021, included in the Annual Report on Form 10-K filed by the Company with the SEC on February 24, 2022. As discussed in Note 3, Discontinued Operations, on December 31, 2021, the Company completed the sale of its KaVo dental treatment unit and instrument business (the "KaVo Treatment Unit and Instrument Business"), which was part of the Company’s Equipment and Consumables segment. The previously reported amounts for the KaVo Treatment Unit and Instrument Business have been reclassified to discontinued operations for all periods presented. All segment information and descriptions exclude the KaVo Treatment Unit and Instrument Business. Risks and Uncertainties The Company is subject to risks and uncertainties as a result of the novel coronavirus (“COVID-19”) pandemic. During the three and six months ended July 1, 2022, notwithstanding improvement in many markets in which the Company operates due to a return to more normalized business operations, certain markets continue to be adversely impacted either directly attributable to COVID-19 or as a result of prior COVID-19 influenced policies. Late in the first quarter of 2022, the Chinese authorities instituted COVID-19-related lockdowns, shut-downs and restrictions in certain parts of China, specifically the Shanghai area, which impacted the Company’s operations in China. These restrictions were lifted in early June 2022, but the extent to which continuing effects from these restrictions and any future restrictions may impact our operations remains uncertain. The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the scope and duration of the pandemic, the rise of new variants, the extent and severity of the impact on the Company's customers, the measures that have been and may be taken to contain the virus (including its various mutations) and mitigate its impact, U.S. and foreign government actions to respond to the reduction in global economic activity, the ability of the Company to continue to manufacture and source its products and to find suitable alternative products at reasonable prices, the Company’s ability to continue to ship and deliver its products in a cost-effective and timely manner, uncertain demand, staffing shortages, the impact of the pandemic and associated economic downturn on the Company’s ability to access capital if and when needed and how quickly and to what extent normal economic and operating conditions can resume, all of which are uncertain and cannot be predicted. Even after the COVID-19 pandemic has subsided, the Company may continue to experience materially adverse impacts on the Company’s financial condition and results of operations. In addition, Russia’s invasion of Ukraine and the global response to this invasion, including sanctions imposed by the U.S. and other countries, could have an adverse impact on the Company’s business, including impacting the Company’s ability to market and sell products in the affected regions, impacting its ability to enforce its intellectual property rights in Russia, creating disruptions in the global supply chain, and by potentially having an adverse impact on the global economy, financial markets, energy markets, currency rates and otherwise. Accounting Standards Recently Adopted In October 2021, the FASB issued ASU No. 2021-08, Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (Topic 805) , which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts, rather than at fair value. This standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The Company adopted this guidance on January 1, 2022, which did not have a significant impact on the Company’s Condensed Consolidated Financial Statements. In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40),” (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This guidance is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU was effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Effective January 1, 2022, the Company adopted ASU 2020-06 using the modified retrospective adoption approach. The cumulative effect of the change was recognized as an adjustment to the opening balance of retained earnings at the date of adoption. The comparative prior year information has not been restated and continues to be presented according to accounting standards in effect for those periods. The adoption of ASU 2020-06 resulted in a $75.0 million increase to the carrying value of the convertible notes due 2025, net of deferred debt issuance costs and unamortized discount and a decrease to additional paid-in capital of $77.8 million. Additionally, the adoption resulted in a $21.4 million increase to retained earnings and a $18.6 million decrease to the related net deferred tax liability associated with the reduction of unamortized debt discount and deferred debt issuance costs. Refer to Note 13 for a further discussion of the impact of adopting ASU 2020-06. Accounting Standards Not Yet Adopted In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform, if certain criteria are met. The ASU is effective for public entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments to eligible hedging relationships existing as of the beginning of the interim period that includes March 12, 2020 and to new eligible hedging relationships entered into after the beginning of the interim period that includes March 12, 2020. If an entity elects to apply any of the amendments for an eligible hedging relationship existing as of the beginning of the interim period that includes March 12, 2020, any adjustments as a result of those elections must be reflected as of the beginning of that interim period and recognized in accordance with the guidance in Reference Rate Reform Subtopics 848-30, 848-40, and 848-50 (as applicable). If an entity elects to apply any of the amendments for a new hedging relationship entered into as of the beginning of the interim period that includes March 12, 2020, any adjustments as a result of those elections must be reflected as of the beginning of the hedging relationship and recognized in accordance with the guidance in Reference Rate Reform Subtopics 848-30, 848-40, and 848-50 (as applicable).

Acquisition

Acquisition	6 Months Ended
	Jul. 01, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisition	ACQUISITION On April 20, 2022, the Company completed its acquisition of Carestream Dental Technology Parent Limited’s (“Carestream”) intraoral scanner business (the “Intraoral Scanner Business”) for total consideration of $580.0 million, including contingent consideration of $7.5 million, and subject to certain customary adjustments as provided in the Stock and Asset Purchase Agreement dated December 21, 2021and as subsequently amended by the closing agreement dated as of April 20, 2022. The Intraoral Scanner Business manufactures, markets, sells, commercializes, distributes, services, trains, supports, and maintains operations of intraoral scanners and software. The Company purchased the Intraoral Scanner Business through the acquisition of certain assets and the assumption of certain liabilities as well as the acquisition of all of the equity of certain subsidiaries of Carestream. The Company continually evaluates potential acquisitions that either strategically fit with the Company’s existing portfolio or expand the Company’s portfolio into new and attractive business areas. The Company has completed a number of acquisitions that have been accounted for as business combinations and have resulted in the recognition of goodwill in the Company’s financial statements. Among other things, goodwill arises because the purchase prices for these businesses reflect a number of factors including the future earnings and cash flow potential of these businesses, the multiple to earnings, cash flow and other factors at which similar businesses have been purchased by other acquirers, the competitive nature of the processes by which the Company acquired the businesses, avoidance of the time and costs which would be required (and the associated risks that would be encountered) to enhance the Company’s existing product offerings to key target markets and enter into new and profitable businesses and the complementary strategic fit and resulting synergies these businesses bring to existing operations. The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities. The Company obtains this information during due diligence and through other sources. In the months after closing, up to 12 months, as the Company obtains additional information that existed at the acquisition date about these assets and liabilities, it is able to refine the estimates of fair value and more accurately allocate the purchase price. Only items that existed as of the acquisition date are considered for subsequent adjustment. The finalization of the acquisition accounting valuation assessment may result in a change in the valuation of the deferred tax assets and goodwill, which could have a material impact on the Company’s financial statements. The following table summarizes the fair values of the assets acquired and liabilities assumed as of the acquisition date ($ in millions): April 20, 2022 Assets acquired: Cash $ 2.7 Accounts receivable 0.1 Inventories 6.2 Intangible assets 129.8 Property, plant and equipment 0.4 Goodwill 370.1 Non-current deferred tax asset 98.5 Other long-term assets 1.1 Total assets acquired 608.9 Liabilities assumed: Accounts payable (0.5) Accrued expenses and other liabilities (27.9) Other long-term liabilities (0.5) Total liabilities assumed (28.9) Total net assets acquired $ 580.0 The intangible assets acquired consist of developed technology and distributor relationships. The weighted average amortization period of the acquired intangible assets in the aggregate is 8 years. The excess of the purchase price over the fair value assigned to the assets acquired and liabilities assumed represents the goodwill resulting from the acquisition. Goodwill attributable to the acquisition has been recorded as a non-current asset and is not amortized, but is subject to review at least on an annual basis for impairment. Goodwill recognized was primarily attributable to expected operating efficiencies and expansion opportunities in the business acquired. The goodwill has been allocated to the Company’s Equipment & Consumables reportable segment and is not deductible for income tax purposes. For the three and six months ended July 1, 2022, legal, accounting, and other professional service costs associated with the acquisition of the Intraoral Scanner Business were $8.2 million and $10.7 million, respectively and have been recorded as selling, general and administrative expense in the Condensed Consolidated Statements of Income. For the three and six months ended July 1, 2022, the Intraoral Scanner Business’ revenue and earnings were not material to the Condensed Consolidated Statements of Income and therefore, the pro forma impact of this acquisition is not presented.

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jul. 01, 2022
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	DISCONTINUED OPERATIONS On December 31, 2021, the Company completed the sale of substantially all of the KaVo Treatment Unit and Instrument Business (the “Divestiture”) to planmeca Verwaltungs Gmbh, Germany (“Planmeca”), pursuant to the master sale and purchase agreement (the “Purchase Agreement”) among the Company, Planmeca, and Planmeca Oy, as guarantor. In accordance with the terms of the Purchase Agreement, the Company received cash consideration of $317.3 million upon closing, which remains subject to certain adjustments. In addition, the Company received an earnout payment of $30.0 million during the first six months of 2022. On December 30, 2021, the Company entered into an amendment to the Purchase Agreement (the "Amendment"), providing that the transfer of net assets in Russia, China and Brazil (the "Relevant Jurisdictions") will be deferred until the purchaser has formed entities for such transfer of assets in each such Relevant Jurisdiction and the applicable asset transfer agreement can be executed and consummated (each such asset transfer, a "Deferred Local Closing"). Except for the implementation of the Deferred Local Closings and related matters regarding the assets in the Relevant Jurisdictions, the provisions, terms and conditions of the Purchase Agreement were not materially amended by the Amendment. The Amendment did not alter the preliminary purchase price that Planmeca paid to the Company upon the closing of the Divestiture. The Company recognized a liability of $4.0 million and$10.8 million for the proceeds related to the Relevant Jurisdictions as of July 1, 2022, and December 31, 2021, respectively. The Company will recognize the applicable gain or loss at the time of each Relevant Jurisdiction’s applicable closing. As of July 1, 2022, one of the Relevant Jurisdictions has closed. The remaining Relevant Jurisdictions are expected to close at various points throughout 2022. The Company recognized a gain of $2.7 million and $7.3 million on the Divestiture during the three and six months ended July 1, 2022, respectively, primarily due to the recognition of certain purchase price adjustments and the closing of one of the Relevant Jurisdictions. In conjunction with the Divestiture, the Company entered into a customary transition services agreement, which requires support transition services to Planmeca throughout the applicable transition period. For the three and six months ended July 1, 2022, the Divestiture continued to meet the criteria to be classified as held for sale and to be presented as a discontinued operation. Accordingly, the Company reclassified the results of operations and financial position of the Divestiture to discontinued operations in its accompanying Condensed Consolidated Statements of Income and Condensed Consolidated Balance Sheets for all periods presented. The Company’s Condensed Consolidated Statements of Cash Flows for all periods presented include the financial results of the KaVo Treatment Unit and Instrument Business. For the six months ended July 2, 2021, balances represent activity for the entire Divestiture, while balances for the six months ended July 1, 2022, represent activity for the remaining Relevant Jurisdictions. The carrying amounts of the assets and liabilities of the Divestiture held for sale are as follows ($ in millions): As of July 1, 2022 December 31, 2021 ASSETS Current assets: Assets for relevant jurisdictions $ 4.1 $ 12.2 Current assets held for sale $ 4.1 $ 12.2 LIABILITIES AND EQUITY Current liabilities: Liabilities for relevant jurisdictions $ 1.7 $ 4.0 Current liabilities held for sale $ 1.7 $ 4.0 The operating results of the Divestiture are reflected in the Condensed Consolidated Statements of Income within income from discontinued operations, net of tax as follows ($ in millions): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Sales $ 2.0 $ 102.9 $ 8.9 $ 199.5 Cost of sales 1.1 59.6 7.0 117.3 Gross profit 0.9 43.3 1.9 82.2 Operating expenses: Selling, general and administrative 1.0 23.7 2.1 45.1 Research and development — 4.4 — 8.7 Operating (loss) profit (0.1) 15.2 (0.2) 28.4 Income tax expense — 4.1 7.4 (Loss) income from discontinued operations (0.1) 11.1 (0.2) 21.0 Gain on sale of discontinued operations, net of tax 2.7 — 7.3 — Net income from discontinued operations $ 2.6 $ 11.1 $ 7.1 $ 21.0 Significant non-cash operating items and capital expenditures for the Divestiture are reflected in the cash flows from operations as follows ($ in millions): Six Months Ended July 1, 2022 July 2, 2021 Cash flows from operating activities Depreciation and amortization 1 $ — $ 3.3 Cash flows from investing activities: Capital expenditures $ — $ 2.4 1 Depreciation and amortization were no longer recognized once the business was classified as discontinued operations as of August 27, 2021.

Credit Losses

Credit Losses	6 Months Ended
	Jul. 01, 2022
Credit Loss [Abstract]
Credit Losses	CREDIT LOSSES The allowance for credit losses is a valuation account deducted from accounts receivable to present the net amount expected to be collected. Accounts receivable are charged off against the allowance when management believes the uncollectibility of an accounts receivable balance is confirmed. Management estimates the adequacy of the allowance by using relevant available information, from internal and external sources, relating to past events, current conditions and forecasts. Historical credit loss experience provides the basis for estimation of expected credit losses and is adjusted as necessary using the relevant information available. The allowance for credit losses is measured on a collective basis when similar risk characteristics exist. The Company has identified one portfolio segment based on the following risk characteristics: geographic regions, product lines, default rates and customer specific factors. The factors used by management in its credit loss analysis are inherently subject to uncertainty. If actual results are not consistent with management’s estimates and assumptions, the allowance for credit losses may be overstated or understated and a charge or credit to net income (loss) may be required. The rollforward of the allowance for credit losses is summarized as follows ($ in millions): Balance at December 31, 2021 $ 20.7 Foreign currency translation (0.9) Provision for credit losses 3.6 Write-offs charged against the allowance (2.3) Recoveries (1.5) Balance at July 1, 2022 $ 19.6

Inventories

Inventories	6 Months Ended
	Jul. 01, 2022
Inventory Disclosure [Abstract]
Inventories	INVENTORIES The classes of inventory are summarized as follows ($ in millions): July 1, 2022 December 31, 2021 Finished goods $ 229.8 $ 214.3 Work in process 26.5 22.0 Raw materials 87.3 88.3 Reserve for inventory obsolescence (57.6) (60.8) Total $ 286.0 $ 263.8

Property, Plant And Equipment

Property, Plant And Equipment	6 Months Ended
	Jul. 01, 2022
Property, Plant and Equipment [Abstract]
Property, Plant And Equipment	PROPERTY, PLANT AND EQUIPMENT The classes of property, plant and equipment are summarized as follows ($ in millions): July 1, 2022 December 31, 2021 Land and improvements $ 10.5 $ 10.7 Buildings and improvements 156.5 168.7 Machinery, equipment and other assets 360.3 354.5 Construction in progress 50.1 45.6 Gross property, plant and equipment 577.4 579.5 Less: accumulated depreciation (313.3) (315.4) Property, plant and equipment, net $ 264.1 $ 264.1

Goodwill

Goodwill	6 Months Ended
	Jul. 01, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	GOODWILL The following is a rollforward of the Company’s goodwill by segment ($ in millions): Specialty Products & Technologies Equipment & Consumables Total Balance at December 31, 2021 $ 2,029.7 $ 1,102.3 $ 3,132.0 Acquisition — 370.1 370.1 Foreign currency translation (81.1) (31.3) (112.4) Balance at July 1, 2022 $ 1,948.6 $ 1,441.1 $ 3,389.7

Accrued Expenses And Other Liab

Accrued Expenses And Other Liabilities	6 Months Ended
	Jul. 01, 2022
Accrued expenses and other [Abstract]
Accrued expenses and other liabilities	ACCRUED EXPENSES AND OTHER LIABILITIES Accrued expenses and other liabilities were as follows ($ in millions): July 1, 2022 December 31, 2021 Current Noncurrent Current Noncurrent Compensation and benefits $ 139.8 $ 17.1 $ 188.9 $ 17.9 Restructuring-related employee severance, benefits and other 17.8 — 21.9 — Pension benefits 5.6 39.2 5.6 41.7 Taxes, income and other 44.2 93.7 48.1 201.4 Contract liabilities 70.8 8.9 60.1 5.1 Sales and product allowances 72.8 1.4 75.4 1.2 Loss contingencies 8.5 30.9 8.4 30.3 Derivative financial instruments — — 19.6 — Other 179.9 10.1 134.3 6.6 Total $ 539.4 $ 201.3 $ 562.3 $ 304.2

Hedging Transactions And Deriva

Hedging Transactions And Derivative Financial Instruments	6 Months Ended
	Jul. 01, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Hedging Transactions and Derivative Financial Instruments	HEDGING TRANSACTIONS AND DERIVATIVE FINANCIAL INSTRUMENTS The Company uses cross-currency swap derivative contracts to partially hedge its net investments in foreign operations against adverse movements in exchange rates between the U.S. dollar and the euro. The cross-currency swap derivative contracts are agreements to exchange fixed-rate payments in one currency for fixed-rate payments in another currency. The Company maintains cross-currency swap derivative contracts with respect to its $650.0 million senior unsecured term loan facility. These contracts effectively convert the $650.0 million senior unsecured term loan facility to an obligation denominated in euros and partially offsets the impact of changes in currency rates on foreign currency denominated net investments. The changes in the fair value of these instruments are recorded in accumulated other comprehensive loss in equity, in the accompanying Condensed Consolidated Balance Sheets, partially offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive loss as reflected in Note 14. Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive loss into income during the period of change. The interest income or expense from these swaps is recorded in interest expense, net in the Company’s Condensed Consolidated Statements of Income consistent with the classification of interest expense attributable to the underlying debt. These instruments mature in September 2024. The Company also has foreign currency denominated long-term debt in the amount of €208.0 million. This senior unsecured term loan facility represents a partial hedge of the Company’s net investment in foreign operations against adverse movements in exchange rates between the U.S. dollar and the euro. The euro senior unsecured term loan facility is designated and qualifies as a non-derivative hedging instrument. Accordingly, the foreign currency translation of the euro senior unsecured term loan facility is recorded in accumulated other comprehensive loss in equity in the accompanying Condensed Consolidated Balance Sheets, offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive loss in equity (see Note 14). Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive loss into income during the period of change. The euro senior unsecured term loan facility matures in September 2024. Refer to Note 13 for a further discussion of the above loan facilities. The Company uses interest rate swap derivative contracts to reduce its variability of cash flows related to interest payments with respect to its senior unsecured term loans. The interest rate swap contracts exchange interest payments based on variable rates for interest payments based on fixed rates. The changes in the fair value of these instruments are recorded in accumulated other comprehensive loss in equity (see Note 14). Any ineffective portions of the cash flow hedges are reclassified from accumulated other comprehensive loss into income during the period of change. The interest income or expense from these swaps is recorded in interest expense in the Company’s Condensed Consolidated Statements of Income consistent with the classification of interest expense attributable to the underlying debt. The current outstanding interest rate swap matures in September 2022. The following table summarizes the notional values as of July 1, 2022 and July 2, 2021 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive loss (“OCI”) for the three and six months ended July 1, 2022 and July 2, 2021 ($ in millions): Three Months Ended Three Months Ended Notional Amount Gain Recognized in OCI Notional Amount Gain (Loss) Recognized in OCI Interest rate contract $ 250.0 $ 0.7 $ 450.0 $ 1.5 Foreign currency contracts 650.0 36.2 650.0 (6.6) Foreign currency denominated debt 216.6 13.1 246.8 (2.1) Total $ 1,116.6 $ 50.0 $ 1,346.8 $ (7.2) Six Months Ended Six Months Ended Notional Amount Gain Recognized in OCI Notional Amount Gain Recognized in OCI Interest rate contracts $ 250.0 $ 2.5 $ 450.0 $ 3.3 Foreign currency contracts 650.0 54.1 650.0 19.0 Foreign currency denominated debt 216.6 19.9 246.8 14.1 Total $ 1,116.6 $ 76.5 $ 1,346.8 $ 36.4 Gains or losses related to the foreign currency contracts and foreign currency denominated debt are classified as foreign currency translation adjustments in the schedule of changes in OCI in Note 14, as these items are attributable to the Company’s hedges of its net investment in foreign operations. Gains or losses related to the interest rate contracts are classified as cash flow hedge adjustments in the schedule of changes in OCI in Note 14. The Company did not reclassify any deferred gains or losses related to net investment and cash flow hedges from accumulated other comprehensive loss to income during the three and six months ended July 1, 2022 and July 2, 2021. In addition, the Company did not have any ineffectiveness related to net investment and cash flow hedges during the three and six months ended July 1, 2022 and July 2, 2021. The cash inflows and outflows associated with the Company’s derivative contracts designated as net investment hedges are classified in investing activities in the accompanying Condensed Consolidated Statements of Cash Flows. The Company’s derivative instruments, as well as its non-derivative debt instruments designated and qualifying as net investment hedges, were classified in the Company’s Condensed Consolidated Balance Sheets as follows ($ in millions): July 1, 2022 December 31, 2021 Derivative Assets: Other long-term assets $ 38.4 $ — Prepaids and other current assets $ 0.3 $ — Derivative liabilities: Accrued expenses and other liabilities $ — $ 19.6 Nonderivative hedging instruments: Long-term debt $ 216.6 $ 236.5 Amounts related to the Company’s derivatives expected to be reclassified from accumulated other comprehensive loss to net income during the next 12 months are not significant.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jul. 01, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where the Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation; and Level 3 inputs are unobservable inputs based on the Company’s assumptions. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety. A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions): Quoted Prices in Significant Other Significant Total July 1, 2022: Assets: Cross-currency swap derivative contracts $ — $ 38.4 $ — $ 38.4 Interest rate swap derivative contracts $ — $ 0.3 $ — $ — Liabilities: Deferred compensation plans $ — $ 15.6 $ — $ 15.6 Contingent consideration $ — $ — $ 7.5 $ 7.5 December 31, 2021: Liabilities: Interest rate swap derivative contracts $ — $ 2.2 $ — $ 2.2 Cross-currency swap derivative contracts $ — $ 17.4 $ — $ 17.4 Deferred compensation plans $ — $ 16.5 $ — $ 16.5 Derivative Instruments The cross-currency swap derivative contracts are classified as Level 2 in the fair value hierarchy as they are measured using the income approach with the relevant interest rates and foreign currency current exchange rates and forward curves as inputs. The interest rate swap derivative contracts are classified as Level 2 in the fair value hierarchy as they are measured using the income approach with the relevant interest rates and forward curves as inputs. Refer to Note 9 for additional information. Deferred Compensation Plans Certain management employees of the Company participate in nonqualified deferred compensation programs that permit such employees to defer a portion of their compensation, on a pretax basis. All amounts deferred under this plan are unfunded, unsecured obligations and are presented as a component of the Company’s compensation and benefits accrual included in accrued expenses in the accompanying Condensed Consolidated Balance Sheets (refer to Note 8). Participants may choose among alternative earnings rates for the amounts they defer, which are primarily based on investment options within the Company’s 401(k) program. Changes in the deferred compensation liability under these programs are recognized based on changes in the fair value of the participants’ accounts, which are based on the applicable earnings rates on investment options within the Company’s 401(k) program. Amounts voluntarily deferred by employees into the Company stock fund and amounts contributed to participant accounts by the Company are deemed invested in the Company’s common stock and future distributions of such contributions will be made solely in shares of Company common stock, and therefore are not reflected in the above amounts. Contingent Consideration Contingent consideration represents a cash hold back intended to be used for certain liabilities related to the Company’s newly acquired Intraoral Scanner Business (as further discussed in Note 2). Contingent consideration was classified as Level 3 in the fair value hierarchy as the estimated fair value was measured using a probability weighted discounted cash flow model. Fair Value of Financial Instruments The carrying amounts and fair values of the Company’s financial instruments were as follows ($ in millions): July 1, 2022 December 31, 2021 Carrying Amount Fair Value Carrying Amount Fair Value Assets: Cross-currency swap derivative contracts $ 38.4 $ 38.4 $ — $ — Interest rate swap derivative contracts $ 0.3 $ 0.3 $ — $ — Liabilities: Contingent consideration $ 7.5 $ 7.5 $ — $ — Interest rate swap derivative contracts $ — $ — $ 2.2 $ 2.2 Cross-currency swap derivative contracts $ — $ — $ 17.4 $ 17.4 Convertible senior notes due 2025 $ 508.6 $ 1,003.5 $ 432.1 $ 1,162.5 Long-term debt $ 864.1 $ 864.1 $ 883.4 $ 883.4

Warranty

Warranty	6 Months Ended
	Jul. 01, 2022
Commitments and Contingencies Disclosure [Abstract]
Warranty	WARRANTY The Company generally accrues estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly and appropriately maintained. Warranty periods depend on the nature of the product and range from 90 days up to the life of the product. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor and in certain instances estimated property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information regarding expected warranty costs becomes known. The following is a rollforward of the Company’s accrued warranty liability ($ in millions): Balance at December 31, 2021 $ 9.4 Accruals for warranties issued during the year 7.6 Settlements made (7.5) Effect of foreign currency translation (0.3) Balance at July 1, 2022 $ 9.2

Litigation And Contingencies

Litigation And Contingencies	6 Months Ended
	Jul. 01, 2022
Commitments and Contingencies Disclosure [Abstract]
Litigation And Contingencies	LITIGATION AND CONTINGENCIES The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. The Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated and has accrued $39.4 million and $38.7 million as of July 1, 2022 and December 31, 2021, respectively, which are included in accrued liabilities in the Condensed Consolidated Balance Sheets. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; or there are numerous parties involved. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's Condensed Consolidated Balance Sheets, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period.

Debt And Credit Facilities

Debt And Credit Facilities	6 Months Ended
	Jul. 01, 2022
Debt Disclosure [Abstract]
Debt And Credit Facilities	DEBT AND CREDIT FACILITIES The components of the Company’s debt were as follows ($ in millions): July 1, 2022 December 31, 2021 Senior term loan facility due 2024 ($650.0 aggregate principal amount) (the “Term Loan Facility”), net of deferred debt issuance costs of $2.2 and $2.7, respectively $ 647.8 $ 647.3 Senior euro term loan facility due 2024 (€208.0 aggregate principal amount) (the “Euro Term Loan Facility”), net of deferred debt issuance costs of $0.4 and $0.5, respectively 216.3 236.1 Convertible senior notes due 2025 ($517.5 aggregate principal amount), net of deferred debt issuance costs of $8.9 and $8.9, respectively, and unamortized discount of $0.0 and $76.5, respectively 508.6 432.1 Other — 0.3 Total debt 1,372.7 1,315.8 Less: current portion (508.6) (432.4) Long-term debt $ 864.1 $ 883.4 As of July 1, 2022 unamortized debt issuance costs totaled $11.5 million. As of December 31, 2021 unamortized debt issuance costs and discount totaled $88.6 million. Unamortized debt issuance costs and discount have been netted against their respective aggregate principal amounts of the related debt in the table above, and are being amortized to interest expense over the term of the respective debt. Long-Term Indebtedness Credit Agreement On September 20, 2019, the Company entered into a credit agreement (the “Credit Agreement”) with a syndicate of banks under which Envista borrowed approximately $1.3 billion, consisting of the three-year $650.0 million Term Loan Facility and the three-year €600.0 million Euro Term Loan Facility (together with the Term Loan Facility, the “Term Loans”). The Credit Agreement also included the five-year, $250.0 million revolving credit facility (the “Revolving Credit Facility” and together with the Term Loans, the “Senior Credit Facilities”). Pursuant to the Separation Agreement, all of the net proceeds of the Term Loans were paid to Danaher as partial consideration for the Dental business Danaher transferred to Envista. On February 9, 2021, in connection with an amendment to the Credit Agreement, the Company repaid $472.0 million of its Euro Term Loan Facility. On June 15, 2021, the Company entered into an amended and restated credit agreement (the “Amended Credit Agreement”) with a syndicate of banks including Bank of America, N.A. as administrative agent (the “Administrative Agent”). The Amended Credit Agreement amends and restates the Company’s Credit Agreement, originally dated September 20, 2019 (as amended by Amendment No. 1 to Credit Agreement dated as of May 6, 2020, Amendment No. 2 to Credit Agreement dated as of May 19, 2020, and Amendment No. 3 to Credit Agreement dated as of February 9, 2021). Under the Amended Credit Agreement: (a) the maturity date of the Company’s existing Term Loans has been extended to September 20, 2024, (b) the Revolving Credit Facility has been increased from $250.0 million to $750.0 million, (c) the Company may request further increases to the Revolving Credit Facility in an aggregate amount not to exceed $350.0 million, (d) the amount of cash and cash equivalents permitted to be netted in the definition of “Consolidated Funded Indebtedness” has been increased to up to the greater of (i) $250.0 million and (ii) 50% of Consolidated EBITDA as of the most recent measurement period, and (e) the floor on Eurocurrency rate loans applicable to the Revolving Credit Facility and the Term Loan Facility has been reduced to zero, in each case subject to and in accordance with the terms and conditions of the Amended Credit Agreement. The Company paid fees aggregating approximately $2.1 million in connection with the Amended Credit Agreement. The Revolving Credit Facility includes an aggregate principal amount of $750.0 million with a $20.0 million sublimit for the issuance of standby letters of credit. The Revolving Credit Facility can be used for working capital and other general corporate purposes. As of July 1, 2022 and December 31, 2021, there were no borrowings outstanding under the Revolving Credit Facility. Under the Senior Credit Facilities, borrowings bear interest as follows: (1) Eurocurrency Rate Loans (as defined in the Amended Credit Agreement) bear interest at a variable rate equal to the London inter-bank offered (“LIBOR”) rate plus a margin of between 0.785% and 1.625%, depending on the Company’s Consolidated Leverage Ratio (as defined in the Amended Credit Agreement) as of the last day of the immediately preceding fiscal quarter; and (2) Base Rate Loans (as defined in the Amended Credit Agreement) bear interest at a variable rate equal to (a) the highest of (i) the Federal funds rate (as published by the Federal Reserve Bank of New York from time to time) plus 0.50%, (ii) Bank of America’s “prime rate” as publicly announced from time to time and (iii) the Eurocurrency Rate (as defined in the Amended Credit Agreement) plus 1.0%, plus (b) a margin of between 0.00% and 0.625%, depending on the Company’s Consolidated Leverage Ratio as of the last day of the immediately preceding fiscal quarter. In no event will Eurocurrency Rate Loans or Base Rate Loans bear interest at a rate lower than 0.0%. In addition, the Company is required to pay a per annum facility fee of between 0.09% and 0.225% depending on the Company’s Consolidated Leverage Ratio as of the last day of the immediately preceding fiscal quarter and based on the aggregate commitments under the Revolving Credit Facility, whether drawn or not. The interest rates for borrowings under the Term Loan Facility were 2.88% and 1.25% as of July 1, 2022 and December 31, 2021, respectively. The interest rate for borrowings under the Euro Term Loan Facility was 1.08% and 0.95% as of July 1, 2022 and December 31, 2021, respectively. Interest is payable quarterly for the Term Loans. The Company has entered into interest rate swap derivative contracts for the Term Loan Facility, as further discussed in Note 9. The Amended Credit Agreement requires the Company to maintain a Consolidated Leverage Ratio of 3.75 to 1.00 or less and includes a provision that the maximum Consolidated Leverage Ratio will be increased to 4.25 to 1.00 for the four consecutive full fiscal quarters immediately following the consummation of any acquisition by the Company or any subsidiary of the Company in which the purchase price exceeds $100.0 million. The Amended Credit Agreement also requires the Company to maintain a Consolidated Interest Coverage Ratio (as defined in the Amended Credit Agreement) of at least 3.00 to 1.00. The Amended Credit Agreement contains customary representations, warranties, conditions precedent, events of default, indemnities and affirmative and negative covenants, including covenants that, among other things, limit or restrict the Company’s and/or the Company’s subsidiaries ability, subject to certain exceptions and qualifications, to incur liens or indebtedness, merge, consolidate or sell or otherwise transfer assets, make dividends or distributions, enter into transactions with the Company’s affiliates and use proceeds of the debt financing for other than permitted uses. The Amended Credit Agreement also contains customary events of default. Upon the occurrence and during the continuance of an event of default, the lenders may declare the outstanding advances and all other obligations under the Amended Credit Agreement immediately due and payable. The Company was in compliance with all of its debt covenants as of July 1, 2022. Convertible Senior Notes (the “Notes”) On May 21, 2020, the Company issued the Notes due on June 1, 2025, unless earlier repurchased, redeemed or converted. The aggregate principal amount, which includes the initial purchasers’ exercise in full of their option to purchase an additional $67.5 million principal amount of the Notes, was $517.5 million. The net proceeds from the issuance, after deducting purchasers’ discounts and estimated offering expenses, were $502.6 million. The Company used part of the net proceeds to pay for the capped call transactions (“Capped Calls”) as further described below. The Notes accrue interest at a rate of 2.375% per annum, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020. The Notes have an initial conversion rate of 47.5862 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $21.01 per share of the Company’s common stock and is subject to adjustment upon the occurrence of specified events. The Notes are governed by an indenture dated as of May 21, 2020 (the “Indenture”) between the Company and Wilmington Trust, National Association, as trustee. The Indenture does not contain any financial covenants or any restrictions on the payment of dividends, the incurrence of senior debt or other indebtedness or the issuance or repurchase of the Company’s securities by the Company. Prior to the adoption of ASU 2020-06, the Company separated the carrying amounts of the Notes and total issuance costs incurred into liability and equity components. For the Notes, the carrying amount of the liability component was calculated by measuring the fair value of a similar debt instrument that does not have an associated convertible feature, while the carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the Notes. Total issuance costs incurred were then allocated to the liability and equity components of the Notes based on their relative values. Due to the Company’s adoption of ASU 2020-06 on January 1, 2022, as discussed in Note 1, the Notes and related issuance costs incurred are no longer required to be bifurcated into separate liability and equity components. This resulted in a $75.0 million increase to the carrying value of the Notes due 2025, comprised of unamortized discount of $76.5 million and deferred debt issuance costs of $1.5 million and a decrease to additional paid-in capital of $77.8 million. Additionally, the adoption of ASU 2020-06 resulted in a $21.4 million increase to retained earnings and a $18.6 million decrease to the related net deferred tax liability associated with the reduction of unamortized debt discount and deferred debt issuance costs. As of July 1, 2022, the unamortized debt issuance costs on the Notes was $8.9 million and is being amortized over the term of the Notes. The Notes are the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Holders of the Notes may convert their Notes at any time on or after December 2, 2024 until the close of business on the second scheduled trading day preceding the maturity date. Holders of the Notes will also have the right to convert the Notes prior to December 2, 2024, but only upon the occurrence of specified events. In December 2021, the Company made the irrevocable election to settle all Notes conversions through combination settlement, satisfying the principal amount outstanding with cash and any Notes conversion value in excess of the principal amount in cash, shares of the Company’s common stock or a combination of both. If a fundamental change occurs prior to the maturity date, holders of the Notes may require the Company to repurchase all or a portion of their Notes for cash at a repurchase price equal to 100.0% of the principal amount plus any accrued and unpaid interest. In addition, if specific corporate events occur prior to the maturity date, the Company would increase the conversion rate for a holder who elects to convert its Notes in connection with such an event in certain circumstances. As of July 1, 2022 and December 31, 2021, the stock price exceeded 130% of the conversion price of $21.01 in 20 days of the final 30 trading days ended July 1, 2022 and December 31, 2021, which satisfied one of the conditions permitting early conversion by holders of the Notes, therefore, the Notes are classified as short-term debt. The Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after June 1, 2023 and on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding the redemption date, but only if the last reported sale price per share of the Company’s common stock exceeds 130.0% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any Note for redemption will constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption. The following table sets forth total interest expense recognized related to the Notes ($ in millions): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Contractual interest expense $ 3.0 $ 3.0 $ 6.1 $ 6.1 Amortization of debt issuance costs 0.8 0.4 1.5 0.9 Amortization of debt discount — 4.7 — 9.3 Total interest expense $ 3.8 $ 8.1 $ 7.6 $ 16.3 For the three and six months ended July 1, 2022, the debt discount and debt issuance costs were amortized using an annual effective interest rate of 3.0%, to interest expense over the term of the Notes. As of July 1, 2022 and December 31, 2021, the if-converted value of the Notes exceeded the outstanding principal amount by $446.4 million and $592.1 million, respectively. Capped Call Transactions In connection with the offering of the Notes, the Company entered into Capped Calls with certain counterparties. The Capped Calls each have an initial strike price of approximately $21.01 per share, subject to certain adjustments, which corresponds to the initial conversion price of the Notes. The Capped Calls have initial cap prices of $23.79 per share, subject to certain adjustments. The Capped Calls cover, subject to anti-dilution adjustments, 2.9 million shares of the Company's common stock. The Capped Calls are generally intended to reduce or offset the potential dilution from shares of common stock issued upon any conversion of the Notes with such reduction or offset, as the case may be, subject to a cap based on the cap price. As the Capped Call transactions are considered indexed to the Company's own stock and are considered equity classified, they are recorded in equity and are not accounted for as derivatives. The cost of $20.7 million incurred in connection with the Capped Calls was recorded as a reduction to additional paid-in capital.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Jul. 01, 2022
Equity [Abstract]
Accumulated Other Comprehensive Loss	ACCUMULATED OTHER COMPREHENSIVE LOSS The changes in accumulated other comprehensive loss by component are summarized below ($ in millions). Foreign Currency Translation Adjustments Unrealized (Loss) Gain on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Three Months Ended July 1, 2022 Balance, April 1, 2022 $ (199.2) $ (0.3) $ (2.3) $ (201.8) Other comprehensive (loss) income before reclassifications: (Decrease) increase (60.4) 0.7 — (59.7) Income tax impact (12.5) (0.2) — (12.7) Other comprehensive (loss) income before reclassifications, net of income taxes (72.9) 0.5 — (72.4) Amounts reclassified from accumulated other comprehensive loss: Increase — — — — Income tax impact — — (0.1) (0.1) Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.1) (0.1) Net current period other comprehensive (loss) income, net of income taxes (72.9) 0.5 (0.1) (72.5) Balance, July 1, 2022 $ (272.1) $ 0.2 $ (2.4) $ (274.3) Foreign Currency Translation Adjustments Unrealized Loss on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Three Months Ended July 2, 2021 Balance, April 2, 2021 $ (116.2) $ (4.9) $ (22.8) $ (143.9) Other comprehensive income before reclassifications: Increase 12.4 1.5 — 13.9 Income tax impact 2.0 (0.4) — 1.6 Other comprehensive income before reclassifications, net of income taxes 14.4 1.1 — 15.5 Amounts reclassified from accumulated other comprehensive loss: Increase — — (0.4) (0.4) Income tax impact — — (0.1) (0.1) Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.5) (0.5) Net current period other comprehensive income, net of income taxes 14.4 1.1 (0.5) 15.0 Balance, July 2, 2021 $ (101.8) $ (3.8) $ (23.3) $ (128.9) Foreign Currency Translation Adjustments Unrealized (Loss) Gain on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Six Months Ended July 1, 2022 Balance, December 31, 2021 $ (139.6) $ (1.7) $ (2.2) $ (143.5) Other comprehensive (loss) income before reclassifications: (Decrease) increase (114.2) 2.5 — (111.7) Income tax impact (18.3) (0.6) — (18.9) Other comprehensive (loss) income before reclassifications, net of income taxes (132.5) 1.9 — (130.6) Amounts reclassified from accumulated other comprehensive loss: Increase — — (0.2) (0.2) Income tax impact — — — — Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.2) (0.2) Net current period other comprehensive (loss) income, net of income taxes (132.5) 1.9 (0.2) (130.8) Balance, July 1, 2022 $ (272.1) $ 0.2 $ (2.4) $ (274.3) Foreign Currency Translation Adjustments Unrealized Loss on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Six Months Ended July 2, 2021 Balance, December 31, 2020 $ (62.5) $ (6.3) $ (23.0) $ (91.8) Other comprehensive (loss) before reclassifications: (Decrease) increase (31.0) 3.3 — (27.7) Income tax impact (8.3) (0.8) — (9.1) Other comprehensive (loss) income before reclassifications, net of income taxes (39.3) 2.5 — (36.8) Amounts reclassified from accumulated other comprehensive loss: Increase — — (0.2) (0.2) Income tax impact — — (0.1) (0.1) Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.3) (0.3) Net current period other comprehensive (loss) income, net of income taxes (39.3) 2.5 (0.3) (37.1) Balance, July 2, 2021 $ (101.8) $ (3.8) $ (23.3) $ (128.9)

Revenue

Revenue	6 Months Ended
	Jul. 01, 2022
Revenue from Contract with Customer [Abstract]
Revenue	REVENUE The following table presents the Company’s revenues disaggregated by geographical region for the three and six months ended July 1, 2022 and July 2, 2021 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenues. The Company has historically defined emerging markets as developing markets of the world, which prior to the COVID-19 pandemic, experienced extended periods of accelerated growth in gross domestic product and infrastructure, including Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan and Australia). The Company defines developed markets as all markets of the world that are not emerging markets. Three Months Ended July 1, 2022 Three Months Ended July 2, 2021 Specialty Products & Technologies Equipment & Consumables Total Specialty Products & Technologies Equipment & Consumables Total Geographical region: North America $ 179.5 $ 160.3 $ 339.8 $ 172.3 $ 165.1 $ 337.4 Western Europe 100.5 29.4 129.9 96.5 31.5 128.0 Other developed markets 23.0 10.3 33.3 25.3 11.5 36.8 Emerging markets 104.7 38.1 142.8 92.1 42.9 135.0 Total $ 407.7 $ 238.1 $ 645.8 $ 386.2 $ 251.0 $ 637.2 Six Months Ended July 1, 2022 Six Months Ended July 2, 2021 Specialty Products & Technologies Equipment & Consumables Total Specialty Products & Technologies Equipment & Consumables Total Geographical region: North America $ 358.8 $ 316.6 $ 675.4 $ 335.1 $ 329.6 $ 664.7 Western Europe 206.8 61.4 268.2 191.2 62.5 253.7 Other developed markets 47.4 20.6 68.0 50.8 21.8 72.6 Emerging markets 191.8 73.8 265.6 175.6 83.2 258.8 Total $ 804.8 $ 472.4 $ 1,277.2 $ 752.7 $ 497.1 $ 1,249.8 Sales by Major Product Group: Three Months Ended Six Months Ended ($ in millions) July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Consumables $ 544.8 $ 531.6 $ 1,074.7 $ 1,045.6 Equipment 101.0 105.6 202.5 204.2 Total $ 645.8 $ 637.2 $ 1,277.2 $ 1,249.8 Consumable products include implants, prosthetics, orthodontic brackets, aligners and lab products from our Specialty Products & Technologies business segment and traditional consumables such as bonding agents and cements, impression materials, infection prevention products and restorative products from the Company’s Equipment & Consumables business segment. The Company’s equipment products include digital imaging systems, software and other visualization and magnification systems. Remaining Performance Obligations Remaining performance obligations include noncancelable purchase orders, extended warranty and service agreements and do not include revenue from contracts with customers with an original term of one year or less. As of July 1, 2022, the aggregate amount of the transaction price allocated to remaining performance obligations was $46.3 million and the Company expects to recognize revenue on the majority of this amount over the next 12 months. Contract Liabilities The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the Condensed Consolidated Balance Sheets based on the timing of when the Company expects to recognize revenue. As of July 1, 2022 and December 31, 2021, the contract liabilities were $79.7 million and $65.2 million, respectively, and are included within accrued expenses and other liabilities and other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets. Revenue recognized during the six months ended July 1, 2022 and July 2, 2021 that was included in the contract liability balance at December 31, 2021 and December 31, 2020 was $36.1 million and $28.1 million, respectively. Significant Customers Sales to the Company’s largest customer were 12% and 11% of sales for the three and six months ended July 1, 2022, respectively. Sales to the Company’s largest customer were 13% and 12% of sales for the three and six months ended July 2, 2021, respectively. Seasonality Based on historical experience, the Company generally has more sales in the second half of the calendar year than in the first half of the calendar year, with the first quarter typically having the lowest sales of the year. Based on historical customer buying patterns, the Company generally has more sales in the fourth quarter than in any other quarter of the year, driven in particular by capital spending in the Equipment & Consumables segment. As a result of this seasonality in sales, profitability in the Equipment & Consumables segment also tends to be higher in the second half of the year. There are no assurances that these historical trends will continue in the future and the ongoing COVID-19 pandemic may impact these trends.

Restructuring Activities And Re

Restructuring Activities And Related Impairments	6 Months Ended
	Jul. 01, 2022
Restructuring and Related Activities [Abstract]
Restructuring Activities And Related Impairments	RESTRUCTURING ACTIVITIES AND RELATED IMPAIRMENTS Restructuring Activities The Company’s restructuring activities are undertaken as necessary to implement management’s strategy, streamline operations, take advantage of available capacity and resources, and ultimately achieve net cost reductions. These activities generally relate to the realignment of existing manufacturing capacity and closure of facilities and other exit or disposal activities, as it relates to executing the Company’s strategy, either in the normal course of business or pursuant to significant restructuring programs. The related liability which is included in accrued liabilities in the Condensed Consolidated Balance Sheets is summarized below ($ in millions): Employee Severance Facility Exit Total Balance, December 31, 2021 $ 21.4 $ 0.5 $ 21.9 Costs incurred 6.8 3.0 9.8 Paid/settled (10.7) (3.2) (13.9) Balance, July 1, 2022 $ 17.5 $ 0.3 $ 17.8 Restructuring related charges recorded for the three and six months ended July 1, 2022 and July 2, 2021, by segment were as follows ($ in millions): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Specialty Products & Technologies $ 4.2 $ 3.6 $ 8.2 $ 7.0 Equipment & Consumables 9.3 2.5 8.4 4.4 Other 1.3 1.3 1.9 3.8 Total $ 14.8 $ 7.4 $ 18.5 $ 15.2 The restructuring related charges incurred during the three and six months ended July 1, 2022 and July 2, 2021, are reflected in the following captions in the accompanying Condensed Consolidated Statements of Income ($ in millions): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Cost of sales $ 6.9 $ 3.1 $ 6.6 $ 6.0 Selling, general and administrative expenses 7.9 4.3 11.9 9.2 Total $ 14.8 $ 7.4 $ 18.5 $ 15.2

Income Taxes

Income Taxes	6 Months Ended
	Jul. 01, 2022
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company’s effective tax rates from continuing operations of 24.7% and 20.8% for the three and six months ended July 1, 2022, respectively, differ from the U.S. federal statutory rate of 21.0%, primarily due to the Company’s geographical mix of earnings and discrete tax items. The Company’s effective tax rates from continuing operations of (12.9)% and 4.5% for the three and six months ended July 2, 2021, respectively, differ from the U.S. federal statutory rate of 21.0%, primarily due to the Company’s geographical mix of earnings and certain non-recurring Swiss discrete tax benefits.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jul. 01, 2022
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE Earnings per share is calculated by dividing the applicable income by the weighted average number of shares of common stock outstanding for the applicable period. Diluted earnings per share is computed based on the weighted average number of common shares outstanding plus the effect of dilutive potential shares outstanding during the period using the treasury stock method. Dilutive potential common shares include employee equity options, non-vested shares and similar instruments granted by the Company and the assumed conversion impact of the Notes. The Company will settle any Notes conversions through a combination settlement by satisfying the principal amount outstanding with cash and any Notes conversion value in excess of the principal amount in cash or shares in the Company’s common stock or any combination thereof. As such, the Company uses the treasury stock method for the assumed conversion of the Notes to compute the weighted average shares of common stock outstanding for diluted earnings per share. As the Company will settle the principal amount of the Notes in cash upon conversion, the Notes do not have an impact on the Company's diluted earnings per share until the average share price of the Company’s common stock exceeds the conversion price of $21.01 per share in any applicable period. See the computation of earnings per share below for the dilutive impact of the Notes for the three and six months ended July 1, 2022 and July 2, 2021. In connection with the offering of the Notes, the Company entered into Capped Calls (see further discussion in Note 13), which are intended to reduce or offset the potential dilution from shares of common stock issued upon conversion of the Notes. However, this impact is not included when calculating potentially dilutive shares since their effect is anti-dilutive. The Capped Calls will mitigate dilution from the conversion of the Notes up to the Company’s common stock price of $23.79. If the Notes are converted at a price higher than $23.79 per share, the Capped Calls will no longer mitigate dilution from the conversion of the Notes. The table below presents the computation of basic and diluted earnings per share ($ and shares in millions, except per share amounts): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Numerator: Income from continuing operations, net of tax $ 44.5 $ 79.0 $ 114.9 $ 140.8 Income from discontinued operations, net of tax $ 2.6 $ 11.1 $ 7.1 $ 21.0 Net income $ 47.1 $ 90.1 $ 122.0 $ 161.8 Denominator: Weighted-average common shares outstanding used in basic earnings (loss) per share 162.9 161.2 162.6 160.8 Incremental common shares from: Assumed exercise of dilutive options and vesting of dilutive restricted stock units 3.3 4.5 3.8 4.5 Assumed conversion of the Notes 12.3 12.7 12.8 11.9 Weighted average common shares outstanding used in diluted earnings (loss) per share 178.5 178.4 179.2 177.2 Earnings per share: Earnings from continuing operations - basic $ 0.27 $ 0.49 $ 0.71 $ 0.88 Earnings from continuing operations - diluted $ 0.25 $ 0.44 $ 0.64 $ 0.79 Earnings from discontinued operations - basic $ 0.02 $ 0.07 $ 0.04 $ 0.13 Earnings from discontinued operations - diluted $ 0.01 $ 0.06 $ 0.04 $ 0.12 Earnings - basic $ 0.29 $ 0.56 $ 0.75 $ 1.01 Earnings - diluted $ 0.26 $ 0.51 * $ 0.68 $ 0.91 * Earnings per share is computed independently for earnings per share from continuing operations and earnings per share from discontinued operations. The sum of earnings per share from continuing operations and earnings per share from discontinued operations does not equal earnings per share due to rounding. The following table presents the number of outstanding securities not included in the computation of diluted income per share, because their effect was anti-dilutive (in millions): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Stock-based awards 1.9 1.4 1.3 1.0 Total 1.9 1.4 1.3 1.0

Segment Information

Segment Information	6 Months Ended
	Jul. 01, 2022
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company operates and reports its results in two separate business segments, the Specialty Products & Technologies and Equipment & Consumables segments. When determining the reportable segments, the Company aggregated operating segments based on their similar economic and operating characteristics. Operating profit represents total revenues less operating expenses, excluding nonoperating income (expense) and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. The identifiable assets by segment are those used in each segment’s operations. Inter-segment amounts are not significant and are eliminated to arrive at consolidated totals. The Company’s Specialty Products & Technologies products include implants, prosthetics, orthodontic brackets, aligners and lab products. The Company’s Equipment & Consumables products include traditional consumables such as bonding agents and cements, impression materials, infection prevention products and restorative products, while the Company’s equipment products include digital imaging systems, software and other visualization and magnification systems. On December 31, 2021, the Company completed the sale of its KaVo Treatment Unit and Instrument Business, which was part of the Company’s Equipment & Consumables segment. The previously reported amounts for the KaVo Treatment Unit and Instrument Business have been reclassified to discontinued operations for all periods presented. All segment information and descriptions exclude the KaVo Treatment Unit and Instrument Business. Refer to Note 3 for more information on the Company’s discontinued operations. Segment related information is shown below ($ in millions): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Sales: Specialty Products & Technologies $ 407.7 $ 386.2 $ 804.8 $ 752.7 Equipment & Consumables 238.1 251.0 472.4 497.1 Total $ 645.8 $ 637.2 $ 1,277.2 $ 1,249.8 Operating profit and reconciliation to income before taxes from continuing operations: Specialty Products & Technologies $ 74.0 $ 71.7 $ 144.3 $ 150.1 Equipment & Consumables 30.2 40.6 75.7 85.6 Other (39.0) (29.0) (63.3) (57.3) Operating profit 65.2 83.3 156.7 178.4 Nonoperating income (expense): Other income 0.3 0.3 0.6 0.6 Interest expense, net (6.4) (13.6) (12.3) (31.6) Income before taxes from continuing operations $ 59.1 $ 70.0 $ 145.0 $ 147.4 Identifiable assets: July 1, 2022 December 31, 2021 Specialty Products & Technologies $ 3,347.0 $ 3,498.2 Equipment & Consumables 2,563.6 1,946.1 Held for Sale 4.1 12.2 Other 546.3 1,117.7 Total $ 6,461.0 $ 6,574.2

Subsequent Events

Subsequent Events	6 Months Ended
	Jul. 01, 2022
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTOn July 5, 2022, the Company completed its purchase of Osteogenics Biomedical Inc., Allotech LLC and OBI Biologics, Inc. (together "Osteogenics") for total consideration of approximately $129.4 million, subject to certain customary adjustments as provided in the definitive agreement dated May 17, 2022. Osteogenics develops innovative regenerative solutions for periodontists, oral and maxillofacial surgeons, and clinicians involved in implant dentistry throughout the world.

Business And Basis Of Present_2

Business And Basis Of Presentation (Policies)	6 Months Ended
	Jul. 01, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation All revenues and costs as well as assets and liabilities directly associated with the business activity of the Company are included in the financial statements. All significant intercompany accounts and transactions between the businesses comprising the Company have been eliminated in the accompanying Condensed Consolidated Financial Statements. The Condensed Consolidated Financial Statements included herein have been prepared by the Company without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The accompanying Condensed Consolidated Financial Statements contain all adjustments (consisting of only normal recurring adjustments and reclassifications to conform to current year presentation) necessary to present fairly the financial position of the Company as of July 1, 2022 and December 31, 2021, and its results of operations for the three and six month periods ended July 1, 2022 and July 2, 2021 and cash flows for the six month periods ended July 1, 2022 and July 2, 2021. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Consolidated and Combined Financial Statements and accompanying notes for the three years ended December 31, 2021, included in the Annual Report on Form 10-K filed by the Company with the SEC on February 24, 2022. As discussed in Note 3, Discontinued Operations, on December 31, 2021, the Company completed the sale of its KaVo dental treatment unit and instrument business (the "KaVo Treatment Unit and Instrument Business"), which was part of the Company’s Equipment and Consumables segment. The previously reported amounts for the KaVo Treatment Unit and Instrument Business have been reclassified to discontinued operations for all periods presented. All segment information and descriptions exclude the KaVo Treatment Unit and Instrument Business.
Accounting Standards Recently Adopted and Not Yet Adopted	Accounting Standards Recently Adopted In October 2021, the FASB issued ASU No. 2021-08, Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (Topic 805) , which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts, rather than at fair value. This standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The Company adopted this guidance on January 1, 2022, which did not have a significant impact on the Company’s Condensed Consolidated Financial Statements. In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40),” (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This guidance is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU was effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Effective January 1, 2022, the Company adopted ASU 2020-06 using the modified retrospective adoption approach. The cumulative effect of the change was recognized as an adjustment to the opening balance of retained earnings at the date of adoption. The comparative prior year information has not been restated and continues to be presented according to accounting standards in effect for those periods. The adoption of ASU 2020-06 resulted in a $75.0 million increase to the carrying value of the convertible notes due 2025, net of deferred debt issuance costs and unamortized discount and a decrease to additional paid-in capital of $77.8 million. Additionally, the adoption resulted in a $21.4 million increase to retained earnings and a $18.6 million decrease to the related net deferred tax liability associated with the reduction of unamortized debt discount and deferred debt issuance costs. Refer to Note 13 for a further discussion of the impact of adopting ASU 2020-06. Accounting Standards Not Yet Adopted In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform, if certain criteria are met. The ASU is effective for public entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments to eligible hedging relationships existing as of the beginning of the interim period that includes March 12, 2020 and to new eligible hedging relationships entered into after the beginning of the interim period that includes March 12, 2020. If an entity elects to apply any of the amendments for an eligible hedging relationship existing as of the beginning of the interim period that includes March 12, 2020, any adjustments as a result of those elections must be reflected as of the beginning of that interim period and recognized in accordance with the guidance in Reference Rate Reform Subtopics 848-30, 848-40, and 848-50 (as applicable). If an entity elects to apply any of the amendments for a new hedging relationship entered into as of the beginning of the interim period that includes March 12, 2020, any adjustments as a result of those elections must be reflected as of the beginning of the hedging relationship and recognized in accordance with the guidance in Reference Rate Reform Subtopics 848-30, 848-40, and 848-50 (as applicable).

Acquisition (Tables)

Acquisition (Tables)	6 Months Ended
	Jul. 01, 2022
Business Combination and Asset Acquisition [Abstract]
Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the assets acquired and liabilities assumed as of the acquisition date ($ in millions): April 20, 2022 Assets acquired: Cash $ 2.7 Accounts receivable 0.1 Inventories 6.2 Intangible assets 129.8 Property, plant and equipment 0.4 Goodwill 370.1 Non-current deferred tax asset 98.5 Other long-term assets 1.1 Total assets acquired 608.9 Liabilities assumed: Accounts payable (0.5) Accrued expenses and other liabilities (27.9) Other long-term liabilities (0.5) Total liabilities assumed (28.9) Total net assets acquired $ 580.0

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jul. 01, 2022
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations	The carrying amounts of the assets and liabilities of the Divestiture held for sale are as follows ($ in millions): As of July 1, 2022 December 31, 2021 ASSETS Current assets: Assets for relevant jurisdictions $ 4.1 $ 12.2 Current assets held for sale $ 4.1 $ 12.2 LIABILITIES AND EQUITY Current liabilities: Liabilities for relevant jurisdictions $ 1.7 $ 4.0 Current liabilities held for sale $ 1.7 $ 4.0 The operating results of the Divestiture are reflected in the Condensed Consolidated Statements of Income within income from discontinued operations, net of tax as follows ($ in millions): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Sales $ 2.0 $ 102.9 $ 8.9 $ 199.5 Cost of sales 1.1 59.6 7.0 117.3 Gross profit 0.9 43.3 1.9 82.2 Operating expenses: Selling, general and administrative 1.0 23.7 2.1 45.1 Research and development — 4.4 — 8.7 Operating (loss) profit (0.1) 15.2 (0.2) 28.4 Income tax expense — 4.1 7.4 (Loss) income from discontinued operations (0.1) 11.1 (0.2) 21.0 Gain on sale of discontinued operations, net of tax 2.7 — 7.3 — Net income from discontinued operations $ 2.6 $ 11.1 $ 7.1 $ 21.0 Significant non-cash operating items and capital expenditures for the Divestiture are reflected in the cash flows from operations as follows ($ in millions): Six Months Ended July 1, 2022 July 2, 2021 Cash flows from operating activities Depreciation and amortization 1 $ — $ 3.3 Cash flows from investing activities: Capital expenditures $ — $ 2.4 1 Depreciation and amortization were no longer recognized once the business was classified as discontinued operations as of August 27, 2021.

Credit Losses (Tables)

Credit Losses (Tables)	6 Months Ended
	Jul. 01, 2022
Credit Loss [Abstract]
Allowance for Credit Loss	The rollforward of the allowance for credit losses is summarized as follows ($ in millions): Balance at December 31, 2021 $ 20.7 Foreign currency translation (0.9) Provision for credit losses 3.6 Write-offs charged against the allowance (2.3) Recoveries (1.5) Balance at July 1, 2022 $ 19.6

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jul. 01, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	The classes of inventory are summarized as follows ($ in millions): July 1, 2022 December 31, 2021 Finished goods $ 229.8 $ 214.3 Work in process 26.5 22.0 Raw materials 87.3 88.3 Reserve for inventory obsolescence (57.6) (60.8) Total $ 286.0 $ 263.8

Property, Plant And Equipment (

Property, Plant And Equipment (Tables)	6 Months Ended
	Jul. 01, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	The classes of property, plant and equipment are summarized as follows ($ in millions): July 1, 2022 December 31, 2021 Land and improvements $ 10.5 $ 10.7 Buildings and improvements 156.5 168.7 Machinery, equipment and other assets 360.3 354.5 Construction in progress 50.1 45.6 Gross property, plant and equipment 577.4 579.5 Less: accumulated depreciation (313.3) (315.4) Property, plant and equipment, net $ 264.1 $ 264.1

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Jul. 01, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Rollforward and Carrying Value Of Goodwill	The following is a rollforward of the Company’s goodwill by segment ($ in millions): Specialty Products & Technologies Equipment & Consumables Total Balance at December 31, 2021 $ 2,029.7 $ 1,102.3 $ 3,132.0 Acquisition — 370.1 370.1 Foreign currency translation (81.1) (31.3) (112.4) Balance at July 1, 2022 $ 1,948.6 $ 1,441.1 $ 3,389.7

Accrued Expenses And Other Li_2

Accrued Expenses And Other Liabilities (Tables)	6 Months Ended
	Jul. 01, 2022
Accrued expenses and other [Abstract]
The components of accrued expenses and other liabilities	Accrued expenses and other liabilities were as follows ($ in millions): July 1, 2022 December 31, 2021 Current Noncurrent Current Noncurrent Compensation and benefits $ 139.8 $ 17.1 $ 188.9 $ 17.9 Restructuring-related employee severance, benefits and other 17.8 — 21.9 — Pension benefits 5.6 39.2 5.6 41.7 Taxes, income and other 44.2 93.7 48.1 201.4 Contract liabilities 70.8 8.9 60.1 5.1 Sales and product allowances 72.8 1.4 75.4 1.2 Loss contingencies 8.5 30.9 8.4 30.3 Derivative financial instruments — — 19.6 — Other 179.9 10.1 134.3 6.6 Total $ 539.4 $ 201.3 $ 562.3 $ 304.2

Hedging Transactions And Deri_2

Hedging Transactions And Derivative Financial Instruments (Tables)	6 Months Ended
	Jul. 01, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative instruments, gain (loss)	The following table summarizes the notional values as of July 1, 2022 and July 2, 2021 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive loss (“OCI”) for the three and six months ended July 1, 2022 and July 2, 2021 ($ in millions): Three Months Ended Three Months Ended Notional Amount Gain Recognized in OCI Notional Amount Gain (Loss) Recognized in OCI Interest rate contract $ 250.0 $ 0.7 $ 450.0 $ 1.5 Foreign currency contracts 650.0 36.2 650.0 (6.6) Foreign currency denominated debt 216.6 13.1 246.8 (2.1) Total $ 1,116.6 $ 50.0 $ 1,346.8 $ (7.2) Six Months Ended Six Months Ended Notional Amount Gain Recognized in OCI Notional Amount Gain Recognized in OCI Interest rate contracts $ 250.0 $ 2.5 $ 450.0 $ 3.3 Foreign currency contracts 650.0 54.1 650.0 19.0 Foreign currency denominated debt 216.6 19.9 246.8 14.1 Total $ 1,116.6 $ 76.5 $ 1,346.8 $ 36.4
Schedule of notional amounts of outstanding derivative positions	The following table summarizes the notional values as of July 1, 2022 and July 2, 2021 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive loss (“OCI”) for the three and six months ended July 1, 2022 and July 2, 2021 ($ in millions): Three Months Ended Three Months Ended Notional Amount Gain Recognized in OCI Notional Amount Gain (Loss) Recognized in OCI Interest rate contract $ 250.0 $ 0.7 $ 450.0 $ 1.5 Foreign currency contracts 650.0 36.2 650.0 (6.6) Foreign currency denominated debt 216.6 13.1 246.8 (2.1) Total $ 1,116.6 $ 50.0 $ 1,346.8 $ (7.2) Six Months Ended Six Months Ended Notional Amount Gain Recognized in OCI Notional Amount Gain Recognized in OCI Interest rate contracts $ 250.0 $ 2.5 $ 450.0 $ 3.3 Foreign currency contracts 650.0 54.1 650.0 19.0 Foreign currency denominated debt 216.6 19.9 246.8 14.1 Total $ 1,116.6 $ 76.5 $ 1,346.8 $ 36.4
Schedule of derivative instruments in statement of financial position, fair value	The Company’s derivative instruments, as well as its non-derivative debt instruments designated and qualifying as net investment hedges, were classified in the Company’s Condensed Consolidated Balance Sheets as follows ($ in millions): July 1, 2022 December 31, 2021 Derivative Assets: Other long-term assets $ 38.4 $ — Prepaids and other current assets $ 0.3 $ — Derivative liabilities: Accrued expenses and other liabilities $ — $ 19.6 Nonderivative hedging instruments: Long-term debt $ 216.6 $ 236.5

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jul. 01, 2022
Fair Value Disclosures [Abstract]
Schedule of financial assets and liabilities at carrying and fair value	A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions): Quoted Prices in Significant Other Significant Total July 1, 2022: Assets: Cross-currency swap derivative contracts $ — $ 38.4 $ — $ 38.4 Interest rate swap derivative contracts $ — $ 0.3 $ — $ — Liabilities: Deferred compensation plans $ — $ 15.6 $ — $ 15.6 Contingent consideration $ — $ — $ 7.5 $ 7.5 December 31, 2021: Liabilities: Interest rate swap derivative contracts $ — $ 2.2 $ — $ 2.2 Cross-currency swap derivative contracts $ — $ 17.4 $ — $ 17.4 Deferred compensation plans $ — $ 16.5 $ — $ 16.5 The carrying amounts and fair values of the Company’s financial instruments were as follows ($ in millions): July 1, 2022 December 31, 2021 Carrying Amount Fair Value Carrying Amount Fair Value Assets: Cross-currency swap derivative contracts $ 38.4 $ 38.4 $ — $ — Interest rate swap derivative contracts $ 0.3 $ 0.3 $ — $ — Liabilities: Contingent consideration $ 7.5 $ 7.5 $ — $ — Interest rate swap derivative contracts $ — $ — $ 2.2 $ 2.2 Cross-currency swap derivative contracts $ — $ — $ 17.4 $ 17.4 Convertible senior notes due 2025 $ 508.6 $ 1,003.5 $ 432.1 $ 1,162.5 Long-term debt $ 864.1 $ 864.1 $ 883.4 $ 883.4

Warranty (Tables)

Warranty (Tables)	6 Months Ended
	Jul. 01, 2022
Commitments and Contingencies Disclosure [Abstract]
Warranty accrual	The following is a rollforward of the Company’s accrued warranty liability ($ in millions): Balance at December 31, 2021 $ 9.4 Accruals for warranties issued during the year 7.6 Settlements made (7.5) Effect of foreign currency translation (0.3) Balance at July 1, 2022 $ 9.2

Debt And Credit Facilities (Tab

Debt And Credit Facilities (Tables)	6 Months Ended
	Jul. 01, 2022
Debt Disclosure [Abstract]
Components of debt	The components of the Company’s debt were as follows ($ in millions): July 1, 2022 December 31, 2021 Senior term loan facility due 2024 ($650.0 aggregate principal amount) (the “Term Loan Facility”), net of deferred debt issuance costs of $2.2 and $2.7, respectively $ 647.8 $ 647.3 Senior euro term loan facility due 2024 (€208.0 aggregate principal amount) (the “Euro Term Loan Facility”), net of deferred debt issuance costs of $0.4 and $0.5, respectively 216.3 236.1 Convertible senior notes due 2025 ($517.5 aggregate principal amount), net of deferred debt issuance costs of $8.9 and $8.9, respectively, and unamortized discount of $0.0 and $76.5, respectively 508.6 432.1 Other — 0.3 Total debt 1,372.7 1,315.8 Less: current portion (508.6) (432.4) Long-term debt $ 864.1 $ 883.4
Components of note interest expense	The following table sets forth total interest expense recognized related to the Notes ($ in millions): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Contractual interest expense $ 3.0 $ 3.0 $ 6.1 $ 6.1 Amortization of debt issuance costs 0.8 0.4 1.5 0.9 Amortization of debt discount — 4.7 — 9.3 Total interest expense $ 3.8 $ 8.1 $ 7.6 $ 16.3

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jul. 01, 2022
Equity [Abstract]
Schedule of accumulated other comprehensive income (loss)	The changes in accumulated other comprehensive loss by component are summarized below ($ in millions). Foreign Currency Translation Adjustments Unrealized (Loss) Gain on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Three Months Ended July 1, 2022 Balance, April 1, 2022 $ (199.2) $ (0.3) $ (2.3) $ (201.8) Other comprehensive (loss) income before reclassifications: (Decrease) increase (60.4) 0.7 — (59.7) Income tax impact (12.5) (0.2) — (12.7) Other comprehensive (loss) income before reclassifications, net of income taxes (72.9) 0.5 — (72.4) Amounts reclassified from accumulated other comprehensive loss: Increase — — — — Income tax impact — — (0.1) (0.1) Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.1) (0.1) Net current period other comprehensive (loss) income, net of income taxes (72.9) 0.5 (0.1) (72.5) Balance, July 1, 2022 $ (272.1) $ 0.2 $ (2.4) $ (274.3) Foreign Currency Translation Adjustments Unrealized Loss on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Three Months Ended July 2, 2021 Balance, April 2, 2021 $ (116.2) $ (4.9) $ (22.8) $ (143.9) Other comprehensive income before reclassifications: Increase 12.4 1.5 — 13.9 Income tax impact 2.0 (0.4) — 1.6 Other comprehensive income before reclassifications, net of income taxes 14.4 1.1 — 15.5 Amounts reclassified from accumulated other comprehensive loss: Increase — — (0.4) (0.4) Income tax impact — — (0.1) (0.1) Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.5) (0.5) Net current period other comprehensive income, net of income taxes 14.4 1.1 (0.5) 15.0 Balance, July 2, 2021 $ (101.8) $ (3.8) $ (23.3) $ (128.9) Foreign Currency Translation Adjustments Unrealized (Loss) Gain on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Six Months Ended July 1, 2022 Balance, December 31, 2021 $ (139.6) $ (1.7) $ (2.2) $ (143.5) Other comprehensive (loss) income before reclassifications: (Decrease) increase (114.2) 2.5 — (111.7) Income tax impact (18.3) (0.6) — (18.9) Other comprehensive (loss) income before reclassifications, net of income taxes (132.5) 1.9 — (130.6) Amounts reclassified from accumulated other comprehensive loss: Increase — — (0.2) (0.2) Income tax impact — — — — Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.2) (0.2) Net current period other comprehensive (loss) income, net of income taxes (132.5) 1.9 (0.2) (130.8) Balance, July 1, 2022 $ (272.1) $ 0.2 $ (2.4) $ (274.3) Foreign Currency Translation Adjustments Unrealized Loss on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Six Months Ended July 2, 2021 Balance, December 31, 2020 $ (62.5) $ (6.3) $ (23.0) $ (91.8) Other comprehensive (loss) before reclassifications: (Decrease) increase (31.0) 3.3 — (27.7) Income tax impact (8.3) (0.8) — (9.1) Other comprehensive (loss) income before reclassifications, net of income taxes (39.3) 2.5 — (36.8) Amounts reclassified from accumulated other comprehensive loss: Increase — — (0.2) (0.2) Income tax impact — — (0.1) (0.1) Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.3) (0.3) Net current period other comprehensive (loss) income, net of income taxes (39.3) 2.5 (0.3) (37.1) Balance, July 2, 2021 $ (101.8) $ (3.8) $ (23.3) $ (128.9)

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jul. 01, 2022
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue by geographical region and type	The following table presents the Company’s revenues disaggregated by geographical region for the three and six months ended July 1, 2022 and July 2, 2021 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenues. The Company has historically defined emerging markets as developing markets of the world, which prior to the COVID-19 pandemic, experienced extended periods of accelerated growth in gross domestic product and infrastructure, including Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan and Australia). The Company defines developed markets as all markets of the world that are not emerging markets. Three Months Ended July 1, 2022 Three Months Ended July 2, 2021 Specialty Products & Technologies Equipment & Consumables Total Specialty Products & Technologies Equipment & Consumables Total Geographical region: North America $ 179.5 $ 160.3 $ 339.8 $ 172.3 $ 165.1 $ 337.4 Western Europe 100.5 29.4 129.9 96.5 31.5 128.0 Other developed markets 23.0 10.3 33.3 25.3 11.5 36.8 Emerging markets 104.7 38.1 142.8 92.1 42.9 135.0 Total $ 407.7 $ 238.1 $ 645.8 $ 386.2 $ 251.0 $ 637.2 Six Months Ended July 1, 2022 Six Months Ended July 2, 2021 Specialty Products & Technologies Equipment & Consumables Total Specialty Products & Technologies Equipment & Consumables Total Geographical region: North America $ 358.8 $ 316.6 $ 675.4 $ 335.1 $ 329.6 $ 664.7 Western Europe 206.8 61.4 268.2 191.2 62.5 253.7 Other developed markets 47.4 20.6 68.0 50.8 21.8 72.6 Emerging markets 191.8 73.8 265.6 175.6 83.2 258.8 Total $ 804.8 $ 472.4 $ 1,277.2 $ 752.7 $ 497.1 $ 1,249.8 Sales by Major Product Group: Three Months Ended Six Months Ended ($ in millions) July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Consumables $ 544.8 $ 531.6 $ 1,074.7 $ 1,045.6 Equipment 101.0 105.6 202.5 204.2 Total $ 645.8 $ 637.2 $ 1,277.2 $ 1,249.8

Restructuring Activities And _2

Restructuring Activities And Related Impairments (Tables)	6 Months Ended
	Jul. 01, 2022
Restructuring and Related Activities [Abstract]
Restructuring and related costs	The related liability which is included in accrued liabilities in the Condensed Consolidated Balance Sheets is summarized below ($ in millions): Employee Severance Facility Exit Total Balance, December 31, 2021 $ 21.4 $ 0.5 $ 21.9 Costs incurred 6.8 3.0 9.8 Paid/settled (10.7) (3.2) (13.9) Balance, July 1, 2022 $ 17.5 $ 0.3 $ 17.8
Schedule of restructuring reserve by type of cost	Restructuring related charges recorded for the three and six months ended July 1, 2022 and July 2, 2021, by segment were as follows ($ in millions): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Specialty Products & Technologies $ 4.2 $ 3.6 $ 8.2 $ 7.0 Equipment & Consumables 9.3 2.5 8.4 4.4 Other 1.3 1.3 1.9 3.8 Total $ 14.8 $ 7.4 $ 18.5 $ 15.2 The restructuring related charges incurred during the three and six months ended July 1, 2022 and July 2, 2021, are reflected in the following captions in the accompanying Condensed Consolidated Statements of Income ($ in millions): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Cost of sales $ 6.9 $ 3.1 $ 6.6 $ 6.0 Selling, general and administrative expenses 7.9 4.3 11.9 9.2 Total $ 14.8 $ 7.4 $ 18.5 $ 15.2

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jul. 01, 2022
Earnings Per Share [Abstract]
Schedule of earnings per share, basic and diluted	The table below presents the computation of basic and diluted earnings per share ($ and shares in millions, except per share amounts): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Numerator: Income from continuing operations, net of tax $ 44.5 $ 79.0 $ 114.9 $ 140.8 Income from discontinued operations, net of tax $ 2.6 $ 11.1 $ 7.1 $ 21.0 Net income $ 47.1 $ 90.1 $ 122.0 $ 161.8 Denominator: Weighted-average common shares outstanding used in basic earnings (loss) per share 162.9 161.2 162.6 160.8 Incremental common shares from: Assumed exercise of dilutive options and vesting of dilutive restricted stock units 3.3 4.5 3.8 4.5 Assumed conversion of the Notes 12.3 12.7 12.8 11.9 Weighted average common shares outstanding used in diluted earnings (loss) per share 178.5 178.4 179.2 177.2 Earnings per share: Earnings from continuing operations - basic $ 0.27 $ 0.49 $ 0.71 $ 0.88 Earnings from continuing operations - diluted $ 0.25 $ 0.44 $ 0.64 $ 0.79 Earnings from discontinued operations - basic $ 0.02 $ 0.07 $ 0.04 $ 0.13 Earnings from discontinued operations - diluted $ 0.01 $ 0.06 $ 0.04 $ 0.12 Earnings - basic $ 0.29 $ 0.56 $ 0.75 $ 1.01 Earnings - diluted $ 0.26 $ 0.51 * $ 0.68 $ 0.91 * Earnings per share is computed independently for earnings per share from continuing operations and earnings per share from discontinued operations. The sum of earnings per share from continuing operations and earnings per share from discontinued operations does not equal earnings per share due to rounding.
Schedule of antidilutive securities excluded from computation of earnings per share	The following table presents the number of outstanding securities not included in the computation of diluted income per share, because their effect was anti-dilutive (in millions): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Stock-based awards 1.9 1.4 1.3 1.0 Total 1.9 1.4 1.3 1.0

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jul. 01, 2022
Segment Reporting [Abstract]
Segment results	Segment related information is shown below ($ in millions): Three Months Ended Six Months Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Sales: Specialty Products & Technologies $ 407.7 $ 386.2 $ 804.8 $ 752.7 Equipment & Consumables 238.1 251.0 472.4 497.1 Total $ 645.8 $ 637.2 $ 1,277.2 $ 1,249.8 Operating profit and reconciliation to income before taxes from continuing operations: Specialty Products & Technologies $ 74.0 $ 71.7 $ 144.3 $ 150.1 Equipment & Consumables 30.2 40.6 75.7 85.6 Other (39.0) (29.0) (63.3) (57.3) Operating profit 65.2 83.3 156.7 178.4 Nonoperating income (expense): Other income 0.3 0.3 0.6 0.6 Interest expense, net (6.4) (13.6) (12.3) (31.6) Income before taxes from continuing operations $ 59.1 $ 70.0 $ 145.0 $ 147.4 Identifiable assets: July 1, 2022 December 31, 2021 Specialty Products & Technologies $ 3,347.0 $ 3,498.2 Equipment & Consumables 2,563.6 1,946.1 Held for Sale 4.1 12.2 Other 546.3 1,117.7 Total $ 6,461.0 $ 6,574.2

Business And Basis Of Present_3

Business And Basis Of Presentation - Narrative (Details) $ in Millions	6 Months Ended
	Jul. 01, 2022 USD ($) segment	Apr. 01, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 02, 2021 USD ($)	Apr. 02, 2021 USD ($)	Dec. 31, 2020 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of business segments (in segments) | segment	2
Long-term Debt	$ 1,372.7		$ 1,315.8
Stockholders' equity	(4,016)		(4,058)
Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity	(3,678.4)	$ (3,667.9)	(3,732.6)	$ (3,707.6)	$ (3,691.1)	$ (3,684.4)
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity	$ (610.3)	$ (563.2)	(466.9)	$ (288.2)	$ (198.1)	$ (126.4)
Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net deferred tax liability			18.6
Adjustment | Convertible Debt
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term Debt			75
Adjustment | Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity			77.8
Adjustment | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity			$ (21.4)

Acquisition - Narrative (Detail

Acquisition - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
	Apr. 20, 2022	Jul. 01, 2022	Jul. 01, 2022
Business Acquisition [Line Items]
Contingent consideration		$ 7,500	$ 7,500
Carestream Dental Technology
Business Acquisition [Line Items]
Consideration transferred	$ 580,000
Contingent consideration	$ 7,500
Weighted-average useful life of acquired intangible assets			8 years
Acquisition costs		$ 8,200	$ 10,700

Acquisition - Fair Values of As

Acquisition - Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Jul. 01, 2022	Apr. 20, 2022	Dec. 31, 2021
Assets acquired:
Goodwill	$ 3,389.7		$ 3,132
Carestream Dental Technology
Assets acquired:
Cash		$ 2.7
Accounts receivable		0.1
Inventories		6.2
Intangible assets		129.8
Property, plant and equipment		0.4
Goodwill		370.1
Non-current deferred tax asset		98.5
Other long-term assets		1.1
Total assets acquired		608.9
Liabilities assumed:
Accounts payable		(0.5)
Accrued expenses and other liabilities		(27.9)
Other long-term liabilities		(0.5)
Total liabilities assumed		(28.9)
Total net assets acquired		$ 580

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - Discontinued operations disposed of by sale - Plamenca - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jun. 30, 2022	Jul. 02, 2021	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration						$ 317.3
Proceeds from sale of KaVo treatment unit and instrument business, net				$ 30
Liability for proceeds related to the Relevant Jurisdictions	$ 4		$ 4			$ 10.8
Gain (loss) on disposal	$ 2.7	$ 0	$ 7.3		$ 0

Discontinued Operations - Carry

Discontinued Operations - Carrying Amount of Assets and Liabilities (Details) - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Current assets:
Current assets held for sale	$ 4.1	$ 12.2
Current liabilities:
Current liabilities held for sale	1.7	4
Discontinued operations disposed of by sale | Plamenca
Current assets:
Assets for relevant jurisdictions	4.1	12.2
Current assets held for sale	4.1	12.2
Current liabilities:
Liabilities for relevant jurisdictions	1.7	4
Current liabilities held for sale	$ 1.7	$ 4

Discontinued Operations - Opera

Discontinued Operations - Operating Results (Details) - Discontinued operations disposed of by sale - Plamenca - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales	$ 2	$ 102.9	$ 8.9	$ 199.5
Cost of sales	1.1	59.6	7	117.3
Gross profit	0.9	43.3	1.9	82.2
Operating expenses:
Selling, general and administrative	1	23.7	2.1	45.1
Research and development	0	4.4	0	8.7
Operating (loss) profit	(0.1)	15.2	(0.2)	28.4
Income tax expense	0	4.1		7.4
(Loss) income from discontinued operations	(0.1)	11.1	(0.2)	21
Gain on sale of discontinued operations, net of tax	2.7	0	7.3	0
Net income from discontinued operations	$ 2.6	$ 11.1	$ 7.1	$ 21

Discontinued Operations - Signi

Discontinued Operations - Significant Non-Cash Operating Items and Capital Expenditures (Details) - Discontinued operations disposed of by sale - Plamenca - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021
Cash flows from operating activities
Depreciation and amortization	$ 0	$ 3.3
Cash flows from investing activities:
Capital expenditures	$ 0	$ 2.4

Credit Losses - Narrative (Deta

Credit Losses - Narrative (Details)	6 Months Ended
	Jul. 01, 2022 segment
Credit Loss [Abstract]
Number of portfolio segments (in segments)	1

Credit Losses - Allowance for C

Credit Losses - Allowance for Credit Losses (Details) $ in Millions	6 Months Ended
	Jul. 01, 2022 USD ($)
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 20.7
Foreign currency translation	(0.9)
Provision for credit losses	3.6
Write-offs charged against the allowance	(2.3)
Recoveries	(1.5)
Ending balance	$ 19.6

Inventories - Summary (Details)

Inventories - Summary (Details) - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished goods	$ 229.8	$ 214.3
Work in process	26.5	22
Raw materials	87.3	88.3
Reserve for inventory obsolescence	(57.6)	(60.8)
Total	$ 286	$ 263.8

Property, Plant And Equipment_2

Property, Plant And Equipment (Details) - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	$ 577.4	$ 579.5
Less: accumulated depreciation	(313.3)	(315.4)
Property, plant and equipment, net	264.1	264.1
Land and improvements
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	10.5	10.7
Buildings and improvements
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	156.5	168.7
Machinery, equipment and other assets
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	360.3	354.5
Construction in progress
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	$ 50.1	$ 45.6

Goodwill - Rollforward (Details

Goodwill - Rollforward (Details) $ in Millions	6 Months Ended
	Jul. 01, 2022 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 3,132
Foreign currency translation	(112.4)
Ending balance	3,389.7
Goodwill	370.1
Specialty Products & Technologies
Goodwill [Roll Forward]
Beginning balance	2,029.7
Foreign currency translation	(81.1)
Ending balance	1,948.6
Goodwill	0
Equipment & Consumables
Goodwill [Roll Forward]
Beginning balance	1,102.3
Foreign currency translation	(31.3)
Ending balance	1,441.1
Goodwill	$ 370.1

Accrued Expenses And Other Li_3

Accrued Expenses And Other Liabilities - Summary (Details) - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Current
Compensation and benefits	$ 139.8	$ 188.9
Restructuring-related employee severance, benefits and other	17.8	21.9
Pension benefits	5.6	5.6
Taxes, income and other	44.2	48.1
Contract liabilities	70.8	60.1
Sales and product allowances	72.8	75.4
Loss contingencies	8.5	8.4
Derivative financial instruments	0	19.6
Other	179.9	134.3
Total	539.4	562.3
Noncurrent
Compensation and benefits	17.1	17.9
Restructuring-related employee severance, benefits and other	0	0
Pension benefits	39.2	41.7
Taxes, income and other	93.7	201.4
Contract liabilities	8.9	5.1
Sales and product allowances	1.4	1.2
Loss contingencies	30.9	30.3
Derivative financial instruments	0	0
Other	10.1	6.6
Total	$ 201.3	$ 304.2

Hedging Transactions And Deri_3

Hedging Transactions And Derivative Financial Instruments - Narrative (Details)	Jul. 01, 2022 USD ($)	Jul. 01, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Sep. 20, 2019 USD ($)	Sep. 20, 2019 EUR (€)
Derivative [Line Items]
Total debt	$ 1,372,700,000		$ 1,315,800,000
US term loan due 2024
Derivative [Line Items]
Total debt	647,800,000		647,300,000	$ 650,000,000
Term loan				$ 650,000,000
Euro term loan due 2024
Derivative [Line Items]
Total debt	$ 216,300,000		$ 236,100,000
Term loan | €		€ 208,000,000			€ 600,000,000

Hedging Transactions And Deri_4

Hedging Transactions And Derivative Financial Instruments - Summary of Notional Values and Pretax Impact in Fair Values of Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	$ 1,116.6	$ 1,346.8	$ 1,116.6	$ 1,346.8
Gain (Loss) Recognized in OCI	50	(7.2)	76.5	36.4
Net investment hedging | Interest rate contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	250	450	250	450
Gain (Loss) Recognized in OCI	0.7	1.5	2.5	3.3
Net investment hedging | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	650	650	650	650
Gain (Loss) Recognized in OCI	36.2	(6.6)	54.1	19
Net investment hedging | Foreign currency denominated debt
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	216.6	246.8	216.6	246.8
Gain (Loss) Recognized in OCI	$ 13.1	$ (2.1)	$ 19.9	$ 14.1

Hedging Transactions And Deri_5

Hedging Transactions And Derivative Financial Instruments - Derivative and Nonderivative Debt Instruments (Details) - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Derivatives, Fair Value [Line Items]
Derivative liabilities	$ 0	$ 19.6
Other long-term assets
Derivatives, Fair Value [Line Items]
Derivative assets	38.4	0
Prepaids and other current assets
Derivatives, Fair Value [Line Items]
Derivative assets	0.3	0
Long-term debt
Derivatives, Fair Value [Line Items]
Nonderivative hedging instruments	$ 216.6	$ 236.5

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Liabilities:
Derivative liabilities	$ 0	$ 19.6
Noncurrent deferred compensation liability	15.6	16.5
Contingent consideration	7.5
Quoted Prices in Active Market (Level 1)
Liabilities:
Noncurrent deferred compensation liability	0	0
Contingent consideration	0
Significant Other Observable Inputs (Level 2)
Liabilities:
Noncurrent deferred compensation liability	15.6	16.5
Contingent consideration	0
Significant Unobservable Inputs (Level 3)
Liabilities:
Noncurrent deferred compensation liability	0	0
Contingent consideration	7.5
Cross-currency swap derivative contracts
Liabilities:
Derivative assets	38.4
Derivative liabilities		17.4
Cross-currency swap derivative contracts | Quoted Prices in Active Market (Level 1)
Liabilities:
Derivative assets	0
Derivative liabilities		0
Cross-currency swap derivative contracts | Significant Other Observable Inputs (Level 2)
Liabilities:
Derivative assets	38.4
Derivative liabilities		17.4
Cross-currency swap derivative contracts | Significant Unobservable Inputs (Level 3)
Liabilities:
Derivative assets	0
Derivative liabilities		0
Interest rate swap derivative contracts
Liabilities:
Derivative assets	0
Derivative liabilities		2.2
Interest rate swap derivative contracts | Quoted Prices in Active Market (Level 1)
Liabilities:
Derivative assets	0
Derivative liabilities		0
Interest rate swap derivative contracts | Significant Other Observable Inputs (Level 2)
Liabilities:
Derivative assets	0.3
Derivative liabilities		2.2
Interest rate swap derivative contracts | Significant Unobservable Inputs (Level 3)
Liabilities:
Derivative assets	$ 0
Derivative liabilities		$ 0

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Financial Instruments (Details) - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 7.5
Derivative liabilities	0	$ 19.6
Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	7.5	0
Convertible senior notes due 2025	508.6	432.1
Long-term debt	864.1	883.4
Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	7.5	0
Convertible senior notes due 2025	1,003.5	1,162.5
Long-term debt	864.1	883.4
Cross-currency swap derivative contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	38.4
Derivative liabilities		17.4
Cross-currency swap derivative contracts | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	38.4	0
Derivative liabilities	0	17.4
Cross-currency swap derivative contracts | Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	38.4	0
Derivative liabilities	0	17.4
Interest rate swap derivative contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	0
Derivative liabilities		2.2
Interest rate swap derivative contracts | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	0.3	0
Derivative liabilities	0	2.2
Interest rate swap derivative contracts | Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	0.3	0
Derivative liabilities	$ 0	$ 2.2

Warranty - Narrative (Details)

Warranty - Narrative (Details)	6 Months Ended
	Jul. 01, 2022
Commitments and Contingencies Disclosure [Abstract]
Product warranty period	90 days

Warranty - Warranty Accrual (De

Warranty - Warranty Accrual (Details) $ in Millions	6 Months Ended
	Jul. 01, 2022 USD ($)
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Beginning balance	$ 9.4
Accruals for warranties issued during the year	7.6
Settlements made	(7.5)
Effect of foreign currency translation	(0.3)
Ending balance	$ 9.2

Litigation And Contingencies -

Litigation And Contingencies - Narrative (Details) - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Accrual for legal matters	$ 39.4	$ 38.7

Debt And Credit Facilities - Co

Debt And Credit Facilities - Components Of Debt (Details)	Jul. 01, 2022 USD ($)	Jul. 01, 2022 EUR (€)	Dec. 31, 2021 USD ($)	May 21, 2020 USD ($)	Sep. 20, 2019 USD ($)	Sep. 20, 2019 EUR (€)
Debt Instrument [Line Items]
Total debt	$ 1,372,700,000		$ 1,315,800,000
Less: current portion	(508,600,000)		(432,400,000)
Long-term debt	864,100,000		883,400,000
US term loan due 2024
Debt Instrument [Line Items]
Term loan					$ 650,000,000
Debt issuance costs	2,200,000		2,700,000
Total debt	647,800,000		647,300,000		$ 650,000,000
Euro term loan due 2024
Debt Instrument [Line Items]
Term loan | €		€ 208,000,000				€ 600,000,000
Debt issuance costs	400,000		500,000
Total debt	216,300,000		236,100,000
Other
Debt Instrument [Line Items]
Total debt	0		300,000
Convertible Debt | Convertible senior notes due 2025
Debt Instrument [Line Items]
Term loan				$ 517,500,000
Debt issuance costs	8,900,000		8,900,000
Unamortized discount	0		76,500,000
Total debt	$ 508,600,000		$ 432,100,000

Debt And Credit Facilities - Na

Debt And Credit Facilities - Narrative (Details) $ / shares in Units, shares in Millions					6 Months Ended	12 Months Ended
	Jun. 15, 2021 USD ($)	Feb. 09, 2021 USD ($)	May 21, 2020 USD ($) tradingDay $ / shares shares	Sep. 20, 2019 USD ($)	Jul. 01, 2022 USD ($) tradingDay $ / shares	Dec. 31, 2021 USD ($) tradingDay $ / shares	Jul. 01, 2022 EUR (€)	Apr. 01, 2022 USD ($)	Jul. 02, 2021 USD ($)	Apr. 02, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 20, 2019 EUR (€)
Debt Instrument [Line Items]
Unamortized debt issuance costs and discount					$ 11,500,000	$ 88,600,000
Total borrowings under term loan				$ 1,300,000,000
Senior unsecured revolving credit facility				$ 250,000,000
Rate in excess of Federal funds rate					0.0050		0.0050
Rate in excess of Eurocurrency rate					0.010		0.010
Leverage ratio					3.75		3.75
Contingency provision on the ratio of indebtedness to net capital					4.25		4.25
Contingency provision, purchase price in excess of $100 million					$ 100,000,000
Interest coverage ratio (at least)					3		3
Conversion price (in USD per share) | $ / shares					$ 21.01	$ 21.01
Total debt					$ 1,372,700,000	$ 1,315,800,000
Stockholders' equity					(4,016,000,000)	(4,058,000,000)
Additional Paid-in Capital
Debt Instrument [Line Items]
Stockholders' equity					(3,678,400,000)	(3,732,600,000)		$ (3,667,900,000)	$ (3,707,600,000)	$ (3,691,100,000)	$ (3,684,400,000)
Retained Earnings
Debt Instrument [Line Items]
Stockholders' equity					(610,300,000)	(466,900,000)		$ (563,200,000)	$ (288,200,000)	$ (198,100,000)	$ (126,400,000)
Adjustment
Debt Instrument [Line Items]
Net deferred tax liability						18,600,000
Adjustment | Additional Paid-in Capital
Debt Instrument [Line Items]
Stockholders' equity						77,800,000
Adjustment | Retained Earnings
Debt Instrument [Line Items]
Stockholders' equity						(21,400,000)
Fair Value
Debt Instrument [Line Items]
Fair value of notes					$ 864,100,000	$ 883,400,000
US term loan due 2024
Debt Instrument [Line Items]
Debt instrument, term				3 years
Term loan				$ 650,000,000
Loan facility interest rates					2.88%	1.25%
Total debt				$ 650,000,000	$ 647,800,000	$ 647,300,000
Debt issuance costs					$ 2,200,000	$ 2,700,000
Euro term loan due 2024
Debt Instrument [Line Items]
Debt instrument, term				3 years
Term loan | €							€ 208,000,000					€ 600,000,000
Repayment of debt		$ 472,000,000
Loan facility interest rates					1.08%	0.95%
Total debt					$ 216,300,000	$ 236,100,000
Debt issuance costs					400,000	500,000
Revolving Credit Facility
Debt Instrument [Line Items]
Senior unsecured revolving credit facility	$ 750,000,000			$ 250,000,000
Increase limit of revolving credit facility	350,000,000
Cash and cash equivalent threshold	$ 250,000,000
EBITDA threshold	0.50
Payments of debt restructuring costs	$ 2,100,000
Revolving credit facility maximum borrowing capacity					750,000,000
Line of credit facility, outstanding borrowings					0	0
Revolving Credit Facility | Standby letters of credit
Debt Instrument [Line Items]
Revolving credit facility maximum borrowing capacity					$ 20,000,000
Minimum
Debt Instrument [Line Items]
Facility fee					0.09%
Maximum
Debt Instrument [Line Items]
Facility fee					0.225%
LIBOR | Minimum | Credit facility
Debt Instrument [Line Items]
Margin spread of variable interest rate					0.785%
LIBOR | Maximum | Credit facility
Debt Instrument [Line Items]
Margin spread of variable interest rate					1.625%
Base Rate | Minimum
Debt Instrument [Line Items]
Margin spread of variable interest rate					0%
Base Rate | Maximum
Debt Instrument [Line Items]
Margin spread of variable interest rate					0.625%
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, term				5 years
Convertible Debt | Adjustment
Debt Instrument [Line Items]
Total debt						75,000,000
Unamortized discount (premium), net						76,500,000
Debt issuance and deferred financing costs						1,500,000
Convertible Debt | 2.375% convertible senior notes over allotment option
Debt Instrument [Line Items]
Term loan			$ 67,500,000
Convertible Debt | 2.375% convertible senior notes
Debt Instrument [Line Items]
Term loan			517,500,000
Proceeds from issuance of convertible senior notes			$ 502,600,000
Interest rate			2.375%
Conversion price (in USD per share) | $ / shares			$ 21.01
Total debt					$ 508,600,000	$ 432,100,000
Debt issuance and deferred financing costs					$ 8,900,000
Redemption price			100%
Threshold percentage of stock price trigger			130%		130%	130%
Convertible debt, trading days (in trading days) | tradingDay			20		20	20
Convertible debt, consecutive trading days (in trading days) | tradingDay			30		30	30
Debt issuance costs					$ 8,900,000	$ 8,900,000
Effective interest rate					3%		3%
If-converted value in excess of principal					$ 446,400,000	$ 592,100,000
Convertible debt, conversion ratio			0.0475862
Convertible Debt | 2.375% convertible senior notes, capped calls
Debt Instrument [Line Items]
Conversion price (in USD per share) | $ / shares			$ 23.79
Convertible debt, stock price trigger (in USD per share) | $ / shares			$ 21.01
Convertible debt, capped calls (in shares) | shares			2.9
Convertible debt expense, capped calls			$ 20,700,000

Debt And Credit Facilities - In

Debt And Credit Facilities - Interest Expense (Details) - Convertible Debt - 2.375% convertible senior notes - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Debt Instrument [Line Items]
Contractual interest expense	$ 3	$ 3	$ 6.1	$ 6.1
Amortization of debt issuance costs	0.8	0.4	1.5	0.9
Amortization of debt discount	0	4.7	0	9.3
Total interest expense	$ 3.8	$ 8.1	$ 7.6	$ 16.3

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Rollforward (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jul. 01, 2022	Apr. 01, 2022	Jul. 02, 2021	Apr. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period		$ 4,058			$ 4,058
Total other comprehensive (loss) income, net of income taxes	$ (72.5)		$ 15		(130.8)	$ (37.1)
Balance, end of period	4,016				4,016
Accumulated Other Comprehensive Loss
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period	(201.8)	(143.5)	(143.9)	$ (91.8)	(143.5)	(91.8)
Increase (decrease) before reclassifications	(59.7)		13.9		(111.7)	(27.7)
Income tax impact	(12.7)		1.6		(18.9)	(9.1)
Other comprehensive (loss) income before reclassifications, net of income taxes	(72.4)		15.5		(130.6)	(36.8)
Increase	0		(0.4)		(0.2)	(0.2)
Income tax impact	(0.1)		(0.1)		0	(0.1)
Amounts reclassified from accumulated other comprehensive loss, net of income taxes	(0.1)		(0.5)		(0.2)	(0.3)
Total other comprehensive (loss) income, net of income taxes	(72.5)	(58.3)	15	(52.1)	(130.8)	(37.1)
Balance, end of period	(274.3)	(201.8)	(128.9)	(143.9)	(274.3)	(128.9)
Foreign Currency Translation Adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period	(199.2)	(139.6)	(116.2)	(62.5)	(139.6)	(62.5)
Increase (decrease) before reclassifications	(60.4)		12.4		(114.2)	(31)
Income tax impact	(12.5)		2		(18.3)	(8.3)
Other comprehensive (loss) income before reclassifications, net of income taxes	(72.9)		14.4		(132.5)	(39.3)
Increase	0		0		0	0
Income tax impact	0		0		0	0
Amounts reclassified from accumulated other comprehensive loss, net of income taxes	0		0		0	0
Total other comprehensive (loss) income, net of income taxes	(72.9)		14.4		(132.5)	(39.3)
Balance, end of period	(272.1)	(199.2)	(101.8)	(116.2)	(272.1)	(101.8)
Unrealized Gain (Loss) on Cash Flow Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period	(0.3)	(1.7)	(4.9)	(6.3)	(1.7)	(6.3)
Increase (decrease) before reclassifications	0.7		1.5		2.5	3.3
Income tax impact	(0.2)		(0.4)		(0.6)	(0.8)
Other comprehensive (loss) income before reclassifications, net of income taxes	0.5		1.1		1.9	2.5
Increase	0		0		0	0
Income tax impact	0		0		0	0
Amounts reclassified from accumulated other comprehensive loss, net of income taxes	0		0		0	0
Total other comprehensive (loss) income, net of income taxes	0.5		1.1		1.9	2.5
Balance, end of period	0.2	(0.3)	(3.8)	(4.9)	0.2	(3.8)
Unrealized Pension Costs
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period	(2.3)	(2.2)	(22.8)	(23)	(2.2)	(23)
Increase (decrease) before reclassifications	0		0		0	0
Income tax impact	0		0		0	0
Other comprehensive (loss) income before reclassifications, net of income taxes	0		0		0	0
Increase	0		(0.4)		(0.2)	(0.2)
Income tax impact	(0.1)		(0.1)		0	(0.1)
Amounts reclassified from accumulated other comprehensive loss, net of income taxes	(0.1)		(0.5)		(0.2)	(0.3)
Total other comprehensive (loss) income, net of income taxes	(0.1)		(0.5)		(0.2)	(0.3)
Balance, end of period	$ (2.4)	$ (2.3)	$ (23.3)	$ (22.8)	$ (2.4)	$ (23.3)

Revenue - Disaggregation by Rev

Revenue - Disaggregation by Revenue Type and Geographical Region (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Disaggregation of Revenue [Line Items]
Sales	$ 645.8	$ 637.2	$ 1,277.2	$ 1,249.8
Consumables
Disaggregation of Revenue [Line Items]
Sales	544.8	531.6	1,074.7	1,045.6
Equipment
Disaggregation of Revenue [Line Items]
Sales	101	105.6	202.5	204.2
North America
Disaggregation of Revenue [Line Items]
Sales	339.8	337.4	675.4	664.7
Western Europe
Disaggregation of Revenue [Line Items]
Sales	129.9	128	268.2	253.7
Other developed markets
Disaggregation of Revenue [Line Items]
Sales	33.3	36.8	68	72.6
Emerging markets
Disaggregation of Revenue [Line Items]
Sales	142.8	135	265.6	258.8
Specialty Products & Technologies
Disaggregation of Revenue [Line Items]
Sales	407.7	386.2	804.8	752.7
Specialty Products & Technologies | North America
Disaggregation of Revenue [Line Items]
Sales	179.5	172.3	358.8	335.1
Specialty Products & Technologies | Western Europe
Disaggregation of Revenue [Line Items]
Sales	100.5	96.5	206.8	191.2
Specialty Products & Technologies | Other developed markets
Disaggregation of Revenue [Line Items]
Sales	23	25.3	47.4	50.8
Specialty Products & Technologies | Emerging markets
Disaggregation of Revenue [Line Items]
Sales	104.7	92.1	191.8	175.6
Equipment & Consumables
Disaggregation of Revenue [Line Items]
Sales	238.1	251	472.4	497.1
Equipment & Consumables | North America
Disaggregation of Revenue [Line Items]
Sales	160.3	165.1	316.6	329.6
Equipment & Consumables | Western Europe
Disaggregation of Revenue [Line Items]
Sales	29.4	31.5	61.4	62.5
Equipment & Consumables | Other developed markets
Disaggregation of Revenue [Line Items]
Sales	10.3	11.5	20.6	21.8
Equipment & Consumables | Emerging markets
Disaggregation of Revenue [Line Items]
Sales	$ 38.1	$ 42.9	$ 73.8	$ 83.2

Revenue - Remaining Performance

Revenue - Remaining Performance Obligations (Details) $ in Millions	Jul. 01, 2022 USD ($)
Revenue from Contract with Customer [Abstract]
Remaining performance obligation	$ 46.3
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-02
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction	12 months

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Contract liability	$ 79.7		$ 79.7		$ 65.2
Revenue recognized			$ 36.1	$ 28.1
Revenue Benchmark | Customer Concentration Risk | Largest customer
Disaggregation of Revenue [Line Items]
Concentration risk percentage	12%	13%	11%	12%

Restructuring Activities And _3

Restructuring Activities And Related Impairments - Schedule Of Restructuring And Related Costs (Details) $ in Millions	6 Months Ended
	Jul. 01, 2022 USD ($)
Restructuring Reserve [Roll Forward]
Balance at beginning of year	$ 21.9
Costs incurred	9.8
Paid/settled	(13.9)
Balance at end of year	17.8
Employee Severance and Related
Restructuring Reserve [Roll Forward]
Balance at beginning of year	21.4
Costs incurred	6.8
Paid/settled	(10.7)
Balance at end of year	17.5
Facility Exit and Related
Restructuring Reserve [Roll Forward]
Balance at beginning of year	0.5
Costs incurred	3
Paid/settled	(3.2)
Balance at end of year	$ 0.3

Restructuring Activities And _4

Restructuring Activities And Related Impairments - Schedule Of Restructuring And Other Related Charges By Segment (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 14.8	$ 7.4	$ 18.5	$ 15.2
Specialty Products & Technologies
Restructuring Cost and Reserve [Line Items]
Costs incurred	4.2	3.6	8.2	7
Equipment & Consumables
Restructuring Cost and Reserve [Line Items]
Costs incurred	9.3	2.5	8.4	4.4
Other
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 1.3	$ 1.3	$ 1.9	$ 3.8

Restructuring Activities And _5

Restructuring Activities And Related Impairments - Schedule Of Restructuring Reserve By Type Of Cost (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 14.8	$ 7.4	$ 18.5	$ 15.2
Cost of sales
Restructuring Cost and Reserve [Line Items]
Costs incurred	6.9	3.1	6.6	6
Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 7.9	$ 4.3	$ 11.9	$ 9.2

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details)	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Income Tax Disclosure [Abstract]
Effective tax rate	24.70%	(12.90%)	20.80%	4.50%

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - $ / shares	Jul. 01, 2022	Dec. 31, 2021	May 21, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Conversion price (in USD per share)	$ 21.01	$ 21.01
2.375% convertible senior notes | Convertible Debt
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Conversion price (in USD per share)			$ 21.01
Dilution threshold (in USD per share)	$ 23.79

Earnings Per Share - Components

Earnings Per Share - Components of Basic and Diluted Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended			6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021		Jul. 01, 2022	Jul. 02, 2021
Numerator:
Income from continuing operations, net of tax	$ 44.5	$ 79		$ 114.9	$ 140.8
Income from discontinued operations, net of tax (refer to Note 3)	2.6	11.1		7.1	21
Net income	$ 47.1	$ 90.1		$ 122	$ 161.8
Denominator:
Weighted-average common shares outstanding used in basic earnings per share (in shares)	162.9	161.2		162.6	160.8
Assumed exercise of dilutive options and vesting of dilutive restricted stock units (in shares)	3.3	4.5		3.8	4.5
Assumed conversion of the Notes (in shares)	12.3	12.7		12.8	11.9
Weighted average common shares outstanding used in diluted earnings (loss) per share (in shares)	178.5	178.4		179.2	177.2
Earnings per share:
Earnings from continuing operations - basic (in USD per share)	$ 0.27	$ 0.49		$ 0.71	$ 0.88
Earnings from continuing operations - diluted (in USD per share)	0.25	0.44		0.64	0.79
Earnings from discontinued operations - basic (in USD per share)	0.02	0.07		0.04	0.13
Earnings from discontinued operations - diluted (in USD per share)	0.01	0.06		0.04	0.12
Earnings - basic (in USD per share)	0.29	0.56		0.75	1.01
Earnings - diluted (in USD per share)	$ 0.26	$ 0.51	[1]	$ 0.68	$ 0.91
[1]* Earnings per share is computed independently for earnings per share from continuing operations and earnings per share from discontinued operations. The sum of earnings per share from continuing operations and earnings per share from discontinued operations does not equal earnings per share due to rounding.

Earnings Per Share - Securities

Earnings Per Share - Securities Not Included in the Computation of Diluted Loss Income per Share (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted (loss) income per share (in shares)	1.9	1.4	1.3	1
Stock-based awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted (loss) income per share (in shares)	1.9	1.4	1.3	1

Segment Information - Narrative

Segment Information - Narrative (Details)	6 Months Ended
	Jul. 01, 2022 segment
Segment Reporting [Abstract]
Number of reportable segments (in segments)	2
Number of operating segments (in segments)	2

Segment Information - Segment R

Segment Information - Segment Results (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Sales	$ 645.8	$ 637.2	$ 1,277.2	$ 1,249.8
Operating profit (loss)	65.2	83.3	156.7	178.4
Other income	0.3	0.3	0.6	0.6
Interest expense, net	(6.4)	(13.6)	(12.3)	(31.6)
Income before income taxes	59.1	70	145	147.4
Identifiable assets	6,461		6,461		$ 6,574.2
Other
Segment Reporting Information [Line Items]
Operating profit (loss)	(39)	(29)	(63.3)	(57.3)
Identifiable assets	546.3		546.3		1,117.7
Held for sale | Discontinued operations disposed of by sale
Segment Reporting Information [Line Items]
Held for Sale	4.1		4.1		12.2
Specialty Products & Technologies
Segment Reporting Information [Line Items]
Sales	407.7	386.2	804.8	752.7
Specialty Products & Technologies | Operating segments
Segment Reporting Information [Line Items]
Sales	407.7	386.2	804.8	752.7
Operating profit (loss)	74	71.7	144.3	150.1
Identifiable assets	3,347		3,347		3,498.2
Equipment & Consumables
Segment Reporting Information [Line Items]
Sales	238.1	251	472.4	497.1
Equipment & Consumables | Operating segments
Segment Reporting Information [Line Items]
Sales	238.1	251	472.4	497.1
Operating profit (loss)	30.2	$ 40.6	75.7	$ 85.6
Identifiable assets	$ 2,563.6		$ 2,563.6		$ 1,946.1

Subsequent Events (Details)

Subsequent Events (Details) $ in Millions	Jul. 05, 2022 USD ($)
Subsequent Event | Osteogenics Biomedical Inc
Subsequent Event [Line Items]
Consideration transferred	$ 129.4